WuXi PharmaTech (Cayman) Inc. A (NYSE:WX)

SHANGHAI and WUXI, China, Sept. 22, 2016 /PRNewswire/ -- WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.

In April 2015 WuXi Biologics announced plans to build a $150 million commercial biologics manufacturing facility in Wuxi city. The first phase of construction is complete and commences operation today after 17 months. The new facility accommodates two 1000L disposable bioreactors for perfusion processes and is the largest perfusion biologics manufacturing facility to date in Asia implementing disposable bioreactors.

This added capacity will support WuXi's robust biologics commercial manufacturing pipeline and enable WuXi to maintain its position as the premier biologics manufacturer in China as well as a leader worldwide. The new commercial biologics manufacturing facility will also address the needs of Chinese companies as Marketing Authorization Holder (MAH) system is currently being piloted.

"The opening of the new commercial manufacturing facility marks another milestone for WuXi," said Dr. Ge Li, Chairman and CEO of WuXi AppTec, "We will uphold the highest quality standards to expedite global development of biologics for both international and domestic clients."

"This new facility further strengthens WuXi Biologics' capabilities in integrated biologics discovery, development, and manufacturing services," said Dr. Chris Chen, CEO of WuXi Biologics, "WuXi Biologics is committed to providing a seamless, truly ONE-stop service for our partners and clients from concept to commercialization. "

SHANGHAI, Dec. 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China andthe United States, today announced the completion of its merger (the "Merger") with WuXi Merger Limited ("Merger Sub"), a wholly-owned subsidiary of New WuXi Life Science Limited ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2015 and amended on October 20, 2015 and November 20, 2015, among the Company, Parent and Merger Sub. As a result of the Merger, Parent has acquired the Company (which is now a direct wholly owned subsidiary of Parent) in a cash transaction valued at approximately US$3.3 billion.

Under the terms of the Merger Agreement, which was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2015, all of the Company's ordinary shares (each, a "Share") (including ordinary shares represented by American Depositary Shares ("ADSs"), each representing eight Shares) issued and outstanding immediately prior to the effective time of the Merger have been cancelled in exchange for the right to receive US$5.75 per Share or US$46.00 per ADS, in each case, in cash, without interest and net of any applicable withholding taxes, except for 1,177,079 ADSs held by Hillhouse Capital Fund II, L.P., 651,892 Shares and 49,514 ADSs held by Mr. Xiaozhong Liu, executive vice president and a director of the Company, and 5,778,304 Shares held by Mr. Zhaohui Zhang, senior vice president of operations, head of domestic marketing and a director of the Company, any Shares held by Parent, the Company or any of their subsidiaries, and any Shares (including Shares represented by ADSs) held by the ADS depositary and reserved for issuance and allocation pursuant to the Company's 2007 Employee Share Incentive Plan, in each case issued and outstanding immediately prior to the effective time of the Merger, which were cancelled without payment of any consideration or distribution therefor. No shareholders validly exercised any dissenters' rights under Cayman Islands law.

Shareholders of record as of the effective time of the Merger who are entitled to the merger consideration will receive a letter of transmittal and instructions on how to surrender their ordinary share certificates in exchange for the merger consideration. Shareholders should wait to receive the letter of transmittal before surrendering their ordinary share certificates.

ADS holders of record as of the effective time of the Merger who are entitled to the merger consideration will automatically receive from JPMorgan Chase Bank, N.A., the Company's ADS depositary, US$46.00 per each ADS held by them (less an ADS cancellation fee ofUS$0.05 per ADS) in cash, without interest and net of any applicable withholding taxes, in exchange for the cancellation of such ADSs. Payment of the ADS merger consideration will be made to such ADS holders as soon as practicable after the Company's ADS depositary receives the merger consideration. ADS holders which hold their ADSs in "street name" through their broker, bank or other nominee will not be required to take any action to receive the net ADS merger consideration for their ADSs as the Company's ADS depositary will arrange for the surrender of such ADSs and the remittance of the per ADS merger consideration with The Depository Trust Company (the clearance and settlement system for the ADSs) for distribution to the applicable broker, bank or nominee on behalf of such beneficial owners. Any questions concerning the receipt of the per ADS merger consideration from holders who hold ADSs in "street name" should be directed by such holders to their applicable broker, bank or nominee.

The Company also announced today that it requested that trading of its ADSs on the New York Stock Exchange (the "NYSE") be suspended as of the close of trading on December 10, 2015. The Company requested that the NYSE file a Form 25 with the Securities and Exchange Commission (the "SEC") notifying the SEC of the delisting of its ADSs on the NYSE and the deregistration of the Company's registered securities. The deregistration will become effective 90 days after the filing of the Form 25 or such shorter period as may be determined by the SEC. The Company intends to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, by filing a Form 15 with the SEC in approximately ten days. The Company's obligations to file with the SEC certain reports and forms, including Form 20-F and Form 6-K, will be suspended immediately as of the filing date of the Form 15 and will cease once the deregistration becomes effective

SHANGHAI, China and RALEIGH, N.C., Dec. 07, 2015 (GLOBE NEWSWIRE) -- WuXi PharmaTech (Cayman) Inc. (WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and PRA Health Sciences, Inc. (PRAH), a leading global clinical contract research organization, today announced a restructuring of their relationship for the delivery of clinical trial management services in China, Macau and Hong Kong. The two companies formed a joint venture for this purpose in March 2013.

Under the new arrangement, the portion of the joint venture located in mainland China will become a wholly owned subsidiary of WuXi, and the portion of the joint venture located in Hong Kong will become a wholly owned subsidiary of PRA. In addition, PRA will retain its Strategic Solutions business in China and Hong Kong, which offers custom-built clinical development solutions to sponsors. In connection with this restructuring, PRA and WuXi will form a preferred provider relationship under which WuXi will provide full-service clinical trial services for global clinical trials subcontracted by PRA in China. 

�WuXi approached us to explore the restructuring of our relationship to better align with their current objectives in China,� said PRA�s CEO Colin Shannon.  �This restructuring allows us to continue our strong relationship with WuXi to support our client needs in China and to leverage the business that we have built together.�

�We appreciate PRA�s strong support for the WuXiPRA joint venture over the past three years,� said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. �Even with this change in the structure of our relationship, WuXi and PRA will remain strong business partners in China.� 

SHANGHAI, November 25, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that at an extraordinary general meeting of shareholders held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated as of August 14, 2015 and amended on October 20, 2015 and November 20, 2015, with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub will be merged with and into the Company with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), and to authorize and approve any and all transactions contemplated by the Merger Agreement, including the Merger.

A total of 426,965,520 ordinary shares (including ordinary shares represented by the Company's American depositary shares, or "ADSs", each of which represents eight ordinary shares) were voted in person or by proxy at today's extraordinary general meeting, representing approximately 75.17% of the Company's total outstanding ordinary shares entitled to vote at the extraordinary general meeting. Of those ordinary shares, approximately 97.49% were voted in favor of the proposal to authorize and approve the Merger Agreement and any and all transactions contemplated by the Merger Agreement, including the Merger. The proposal to adopt the Merger Agreement was also approved by 97.33% of ordinary shares present and voting in person or by proxy at the extraordinary general meeting and held by holders that are unaffiliated with the buyer group, satisfying the "majority of the minority" voting requirement set forth in the Merger Agreement.

The parties currently expect to complete the Merger next month, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. If and when completed, the Merger would result in the Company becoming a privately held company, and its ADSs would no longer be listed on the New York Stock Exchange. In addition, the ADSs and the Company's ordinary shares represented by the ADSs will cease to be registered under Section 12 of the Securities Exchange Act of 1934.

SHANGHAI, Nov. 11, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis") have recommended that WuXi shareholders vote FOR the proposal to approve the Company's previously announced agreement and plan of merger (the "Merger Agreement") dated as of August 14, 2015 and amended on October 20, 2015, with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent will acquire the Company for US$5.75 per ordinary share of the Company or US$46 per American depositary share, each representing eight ordinary shares (an "ADS"), in each case, in cash, without interest and net of any applicable withholding taxes, and Merger Sub will be merged with and into the Company with the Company continuing as the surviving corporation and becoming a wholly owned subsidiary of Parent (the "Merger").

ISS and Glass Lewis are leading independent international proxy advisory firms, and their voting analyses and recommendations are relied upon by thousands of major institutional investment firms, mutual funds and fiduciaries throughout the world.  

The Company's extraordinary general meeting of shareholders (the "EGM") to consider and vote on, among other things, the Merger Agreement, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the "Plan of Merger") and the transactions contemplated thereby, including the Merger, will be held on November 25, 2015 at 10:00 a.m. (Shanghai time), at the executive offices of the Company located at 288 Fute Zhong Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, 200131, People's Republic of China.

Shareholders of record at the close of business in the Cayman Islands on November 2, 2015 will be entitled to attend and vote at the EGM. ADS holders as of the close of business in New York City on October 19, 2015 will be entitled to instruct JPMorgan Chase Bank, N.A., in its capacity as the ADS depositary, to vote the shares represented by their ADSs at the EGM, and are reminded that the deadline to deliver their voting instructions to the ADS depositary is 12:00 p.m. (New York City time) on November 20, 2015.

The Company's shareholders and ADS holders are urged to read carefully and in their entirety the Company's definitive proxy materials, as they contain important information about the Company, the proposed Merger and related matters.

SHANGHAI, Nov. 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and Eli Lilly and Company (LLY) today announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.

The potential medicine is a novel, once-daily oral agent, discovered by Lilly, which could address cardiovascular risk in patients with dyslipidemia, representing an unmet medical need worldwide. An estimated 276 million patients in China are affected by these conditions, including about 12 million patients requiring drug treatment. The potential medicine aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events.  

WuXi will be responsible for regulatory, development and manufacturing activities in China, which will be led and coordinated by WuXi's Product Development Service and Partnership (PDSP) Business Unit. The potential medicine will be manufactured in China by WuXi to support China development. Lilly will be responsible for commercial activities. The parties will both invest in bringing this potential new medicine to patients in China. Further financial terms of the collaboration were not disclosed. An Investigational New Drug (IND) application will be filed in China by WuXi, and product development and registration will be carried out within China.

"We are pleased to collaborate with WuXi to develop this potential new medicine," said Andrew Hodge, President of Lilly China. "This unique collaboration is part of our 'In China, For China' strategy to leverage Lilly's leading technology and experience, and local partners' insight and expertise, to meet patient needs."

"WuXi is delighted to work with Lilly, a world-leading pharmaceutical company, to develop, register and manufacture this potential first-in-class therapeutic agent," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This strategic collaboration will leverage the recently announced China regulatory reforms, which strongly encourage, support, and accelerate development and manufacture in China of highly innovative new medicines that target major unmet medical needs."  

NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has entered into a two-year agreement with WuXi AppTec, Inc. ("WuXi AppTec") to provide additional TIL manufacturing capacity. The additional manufacturing capability is expected to become available within the first six months of 2016 at WuXi AppTec's facility in Philadelphia.

"We are pleased to be expanding our cGMP manufacturing capacity with this new relationship with WuXi AppTec," said Elma Hawkins, Ph.D., president and chief executive officer of Lion Biotechnologies. "In conjunction with the capacity we already have available, this relationship with Wuxi AppTec will provide us greater flexibility in support of our development plans for 2016 and into the future."

"We look forward to working with Lion on this exciting approach to immuno-oncology therapy," said Felix Hsu, Senior Vice President, U.S. Operations for WuXi AppTec. "We believe that our fully integrated services and technology platform will be of great benefit to Lion, and we're delighted to help support their development efforts in this exciting field.

Third-Quarter 2015 Financial Results

• Net Revenues Increased 23.1% Year Over Year to $213.6 Million
• Non-GAAP Diluted Earnings Per ADS Attributable to WuXi Shareholders Decreased 41.8% Year Over Year to $0.31, Reflecting Exclusion of Share-Based Compensation of $0.09, Amortization of Acquired Intangible Assets of $0.02, and Deferred Tax Impact Related to Acquired Intangible Assets of ($.01)

SAN ANTONIO, SHANGHAI, CAMBRIDGE, Mass., REYKJAVIK, Iceland, and MADRID, Nov. 3, 2015/PRNewswire/ -- The San Antonio 1000 Cancer Genomes Project (SA1kCGP), WuXi NextCODE, and South Texas Accelerated Research Therapeutics (START) today announced a partnership that will enable San Antonio's pioneering city-wide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for this resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.

START, which operates the world's largest Phase I medical oncology program through clinical sites in the US, China and Spain, has contracted with WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, to sequence and interpret the samples. WuXi NextCODE will utilize its CLIA sequence laboratory and its HIPAA-compliant NextCLOUD™ secondary analysis and storage solution, powered by DNAnexus.  START is connecting this "delta file" to anonymized patient electronic clinical records using the Medidata Rave™ system, and will make it available to qualified researchers and clinicians via the cloud.

"We're excited to announce the next phase in this pioneering effort, turning the talents and generosity of our community into better outcomes for patients," said Aimee Locke, founder and president of SA1kCGP. "As global leaders in clinical development and genomics, and with operations in the US, Europe and China, our partners WuXi NextCODE and START are uniquely placed to help us deliver on this vision."

"Our three organizations share the mission of using our unique capabilities and assets to create better medicine for patients everywhere," said Dr Anthony Tolcher, director of clinical research at START. "WuXi NextCODE was the logical partner in genomics. They bring to this project the same expertise they are deploying in large-scale precision oncology initiatives from Genomics England to Qatar, backed by the renowned clinical development capabilities of WuXi AppTec."

"San Antonio is innovating locally and impacting globally, an approach to precision medicine we are thrilled to be a part of," said Hannes Smarason, co-founder, President and COO of WuXi NextCODE, a wholly owned subsidiary of WuXi AppTec (NYSE: WX). "This is a pathbreaking resource in scope, scale, and with START's hallmark clinical rigor. We are all focused here on speeding the delivery of the latest in genome-driven therapy straight to cancer patients, wherever they may be."

SHANGHAI, Oct. 29, 2015 /PRNewswire/ -- Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.

Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai. The facility will provide analytical and stability services, including analytical method development, transfer and validation for IND/NDA submissions; commercial API and drug product testing; stability studies of APIs, drug products for registration, and commercial products; and reference standard qualification.

"This strategic partnership further strengthens our close, broad-based collaboration with Gilead over many years," said Ge Li, PhD, Chairman and CEO of WuXi PharmaTech. "WuXi is determined to enable our innovative partners like Gilead through our open-access R&D platform, and we are very honored to help advance some of the most innovative medicines faster to patients."

"The opening of this analytical and stability testing center is an important milestone in the ongoing long-term relationship between Gilead and WuXi," said Bob Miller, Vice President of Quality Assurance - Gilead Sciences.

SHANGHAI, October 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has launched a mobile version of OncoWuXi, the first App in the world to allow researchers to access oncology models and data on the go. The OncoWuXi App helps WuXi's clients anywhere and at any time to identify relevant tumor models for use in anti-tumor efficacy testing to facilitate oncology drug discovery and translational oncology, as well as to keep up-to-date on WuXi's capabilities and services in this area.

The OncoWuXi App provides users with a portable oncology database for selection and inquiry of the more than 1,000 cancer patient-derived xenograft (PDX), human cancer cell-derived xenograft (CDX), and syngeneic mouse tumor models available at WuXi. Its backend database covers every aspect of those models, including growth dynamics, histopathology, clinical information, genomic profiles, and Standard of Care (SoC) validation data. Users may also submit service requests regarding particular models from the App directly to WuXi Oncology.

The App can be used on either Apple or Android devices and is available for download at both the Apple App store and Google Play. Its corresponding web-based browser, http://onco.wuxiapptec.com/, was launched in China in June and is also accessible globally.

"WuXi has long been committed to bringing our customers the most advanced products and services for discovering and developing innovative drugs," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Beginning with WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis, which we launched earlier this year, and now with OncoWuXi, we are striving to enable our customers to access our platform capabilities and technologies more quickly and easily."

SHANGHAI and CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Sept. 16, 2015 /PRNewswire/ -- WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and theChildren's Hospital of Fudan University (CHFU), based in Shanghai and serving 2.3 million patients nationwide per year, today announced the signing of a landmark agreement for advancing precision medicine in China. It brings WuXi NextCODE's renowned genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU's preeminence in pediatrics to begin immediately to deliver benefits to thousands of rare disease patients across China.

WuXi NextCODE is deploying the full range of its renowned genome testing infrastructure for CHFU: CLIA sequencing, massively scalable informatics, and the most powerful interpretation tools and clinical genetics expertise. As a result, CHFU will be able to offer Chinese rare disease patients the same sequence-based diagnostics now available to patients in the United States and Europe through partners including Boston Children's Hospital and Genomics England. CHFU, which sees as many as 7,000 patients every day, can now rapidly scale up sequence-based testing to resolve more undiagnosed cases.

"We share a mission with CHFU: to put the best technology in the hands of the best doctors and scientists to help patients," said Dr Ge Li, Chairman and CEO of WuXi AppTec, of which WuXi NextCODE is a wholly owned subsidiary. "We are very excited to join with our friends at CHFU to take the lead in rare disease diagnosis, care and research in China, offering patients world-class testing right here."

"Looking for the genomics infrastructure that could deliver the best results for our patients, we saw that our colleagues at Harvard Medical School and other leading institutions were choosing WuXi NextCODE," saidGuoying Huang, President of CHFU. "We've come to the same conclusion. Using the emerging global standard for genomic data in medicine, we can move beyond static gene panels to employ the full power of the genome to address rare diseases, genetic and genetics-related disorders and eventually cancer and other conditions as well. We can also collaborate instantly with sister institutions that use WuXi NextCODE's system to push the frontiers of care and discovery."

"Our aim is to bring our technology into the clinic to deliver precision medicine to patients in every market worldwide," said Hannes Smarason, co-founder, President and COO of WuXi NextCODE. "China is central to that strategy, and we couldn't have a better partner than Fudan Children's for realizing it and giving thousands of young patients and their families the best diagnostics and treatment options for inherited rare disorders."

SHANGHAI, Aug. 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients (APIs) and GMP intermediates for branded commercial drugs from regulatory agencies in the United States, Canada, the European Union, Switzerland, China, Japan, Australia, and New Zealand.

STA's integrated platform of services, extending from process research to research manufacturing to commercial manufacturing, helps clients move their new chemical entities through preclinical and clinical development to global commercial launch.

"I'm very proud of our track record in securing approvals from global regulatory agencies and the added confidence these successes bring to our partners," said Dr. Minzhang Chen, CEO of STA.

"This favorable outcome further demonstrates that STA's facilities, processes, and people are world-class and of the highest quality," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "We look forward to expanding these capabilities with our new facilities under construction in Changzhou to better serve our partners."

SHANGHAI, August 14, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

Pursuant to the Merger Agreement, Parent will acquire the Company for cash consideration equal to US$5.75 per ordinary share of the Company (each, a "Share") and US$46 per American Depositary Share of the Company, each representing eight Shares (each, an "ADS"), or approximately US$3.3 billion in aggregate cash consideration. This represents a 16.5% premium over the closing price of US$39.50 per ADS as quoted by the New York Stock Exchange (the "NYSE") on April 29, 2015, and a premium of 18.9% and 20.1%, respectively, over the Company's 30- and 60- trading day volume-weighted average price as quoted by the NYSE prior to April 29, 2015, the last trading day prior to the Company's announcement on April 30, 2015 that it had received a non-binding "going private" proposal.

Immediately following the consummation of the transactions contemplated by the Merger Agreement, Parent will be beneficially owned by a consortium (the "Buyer Group") comprised of:

(i) new investors which include affiliates of or funds managed or advised by Ally Bridge Group
Capital Partners ("Ally Bridge"), Boyu Capital ("Boyu Capital"), Temasek Life Sciences
Private Limited ("Temasek") and Ping An Insurance ("Ping An");

(ii) Hillhouse Fund II, L.P. ("Hillhouse", and together with Ally Bridge, Boyu Capital, Temasek,
Ping An and additional sponsors that may be admitted to the Buyer Group, the
"Sponsors"), an existing shareholder of the Company and an affiliate of Hillhouse Capital;
and

(iii) the following founders and executive officers of the Company who have elected to roll-over
their interest in the Company in connection with the Merger (together with entities through
which such individuals own their Shares (including Shares represented by ADSs) (the
"Founders")): Dr. Ge Li, the chairman and chief executive officer, Mr. Xiaozhong Liu, an
executive vice president and a director, Mr. Zhaohui Zhang, a senior vice president of
operations, the head of domestic marketing and a director, and Dr. Ning Zhao, a senior vice
president of operations, the head of corporate human resources and a director.

As of the date of the Merger Agreement, Hillhouse and the Founders (together, the "Rollover Shareholders") beneficially own in aggregate approximately 4.5% of the issued and outstanding Shares.

Second-Quarter 2015 Financial Results

• Net Revenues Increased 18.8% Year Over Year to $194.1 Million
• Non-GAAP Diluted Earnings Per ADS Decreased 21.6% Year Over Year to $0.38

"WuXi had excellent year-over-year revenue growth of 18.8% in the second quarter, meeting the company's expectations," said Dr. Ge Li, Chairman and CEO. "That revenue growth was again broad-based, with double-digit growth from each of the four segments of the business. Revenue growth in our small-molecule manufacturing businesses was slightly lower than expected due to the timing of product deliveries, but this is not expected to impact the full-year performance of this business. The revenue performance of our biologics business exceeded expectations. This overall performance gives us confidence to reconfirm our full-year 2015 revenue guidance of $790-$800 million.

"The quarter was also characterized by significant year-over-year declines in margins and diluted EPS because of sharply increased levels of investment in new businesses," Dr. Li continued. "WuXi today is two groups of businesses -- strong core businesses, and promising, but very challenging, new businesses. Our core businesses are performing well, generating solid revenue and operating income growth. But we also see many compelling investment opportunities in new businesses, such as in genomics / bioinformatics, e-commerce, and China healthcare initiatives, opportunities that we are choosing to seize during this period of strength to drive longterm growth. To date, these new businesses are developing more slowly than we had anticipated.

"As many of you know, the RMB depreciated significantly versus the US dollar earlier this week, and this depreciation could result in significant mark-to-market losses and realized losses on foreign-exchange forward contracts in the third quarter and full year," Dr. Li concluded. "In addition, WuXi is considering several transactions that in comparison to historical results could further reduce margins and diluted EPS in full-year 2015 and beyond. Therefore, because of uncertainties regarding these circumstances, we are withdrawing our GAAP and non-GAAP diluted EPS financial guidance for full-year 2015."

Full-Year 2015 Financial Guidance

WuXi PharmaTech reconfirms full-year 2015 revenue guidance of $790-$800 million. The company withdraws its full-year 2015 guidance for GAAP and non-GAAP diluted EPS because of uncertainties regarding currency exchange-rate volatility and potential significant costs associated with several transactions under consideration. The rapid depreciation of the RMB against the U.S. dollar could result in significant mark-to-market losses and realized losses on foreign-exchange forward contracts.

SHANGHAI and HONOLULU, August 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and TruTag Technologies, Inc., developer of an innovative edible security platform for pharmaceuticals, today announced the successful completion of joint testing of TruTag's on-dose authentication solution.

TruTags offer a unique solution for drug manufacturers, allowing a digital scan of a drug to confirm its authenticity and reveal provenance information such as manufacturing location, dosage, images of packaging, expiration date, supply chain data, and lot or batch number. WuXi and TruTag Technologies announced their alliance in 2014, including an investment by the WuXi Venture Fund in TruTag.

TruTags have a number of benefits for pharmaceutical manufacturers that were confirmed in this joint testing:

• TruTags can be applied to qualifying solid oral dosage form (SODF) products using a consistent, repeatable process.
• No new manufacturing equipment and changes in manufacturing processes are needed.
• After application on manufactured tablets, TruTags are successfully detected using TruTag's proprietary optical detection device.
• Apart from this detection process, TruTags are covert and not visually identifiable and remain with the tablet for its entire life.
• Once applied, the TruTag solution did not affect the stability or dissolution properties of API drugs in completed accelerated open and closed bottle testing.
• Implementing the TruTag solution on existing drugs requires minimal regulatory reporting changes for drug manufacturers and complies with the physical-chemical identifier (PCID) guidance issued by the U.S. Food and Drug Administration in 2011.

WuXi and TruTag will now begin further testing of TruTags on additional API products. They will also produce a technical white paper for the industry detailing the results of the application method and practice, the detection process and data collection, and outcomes of dissolution and stability testing. TruTag is already working with several multinational pharmaceutical companies in pilot testing for broad deployment of this technology in marketed SODF drugs and product candidates.

"We are very excited about these results," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "At WuXi, we are always seeking cutting-edge solutions like TruTags to help support the development and protection of our customers' innovative products."

Kent Mansfield, President of TruTag Technologies, commented, "We are excited to confirm these results in testing conducted with our partner WuXi PharmaTech, an innovative company that values its customers' IP and patients' safety. We have demonstrated the ability of our technology to integrate an edible and safe identification code directly into an oral solid drug, thereby indelibly marking the product with an internal code for its lifetime. In the near term, this will allow drug manufacturers and distributors to have the ultimate audit of a drug's provenance and origin without reliance on packaging or laboratory chemical analysis."

"One can think of TruTags as a form of edible PIATS, or Product Identification Authentication Tracking System, which can be embedded into a product like unique fingerprints," said Hank Wuh, MD, MPH, TruTag Technologies' Founder and Chairman. "With our ability to securely identify individual goods without labels or packaging, we aim to dramatically improve the safety and traceability of critical products such as food and medicine and in the process to have a fundamental impact on big data."

SHANGHAI, July 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that SynTheAll Pharmaceutical Co. Ltd. (STA), WuXi's small-molecule manufacturing subsidiary, has entered into an agreement in connection with a planned private placement of 7,160,000 common shares of STA stock, representing approximately 6% of STA's current shares outstanding, for RMB 498,694,000 in cash, or approximately $80 million at current exchange rates. Purchasers in the private placement (comprised of 33 institutional investors in China) have agreed to a lock-up period of 12 months, the same as for STA and WuXi management who purchased shares. None of the investors purchasing STA stock in the private placement are affiliated with WuXi. After giving effect to the private placement, WuXi will own 89.1% of STA's shares outstanding. The closing of the private placement is subject to customary conditions and is expected to close by the end of July 2015. In April 2015, STA completed the listing of its shares on the New Third Board, the over-the-counter stock exchange in China.

STA provides process chemistry services and manufactures small-molecule advanced intermediates and APIs for customer use in preclinical and clinical trials and for marketed small-molecule drugs. Its operations are located in the Waigaoqiao Free Trade Zone and Jinshan, both in Shanghai, and in Changzhou. STA does not include WuXi's biologics manufacturing business. STA's business is significantly more capital intensive than WuXi's laboratory services business and is in the process of building new facilities in Changzhou to substantially increase its production capacity. The proceeds of this new private placement will fund this capacity expansion and other investments necessary to support STA's future growth.

SHANGHAI, CAMBRIDGE, Mass. and REYKJAVIK, Iceland, June 4, 2015 /PRNewswire/ -- WuXi AppTec today announced a partnership with Fudan University to bring WuXi NextCODE's world-leading population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) as an enterprise partner. The partnership will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis, and treatment of rare inherited diseases and malignant tumors.

As a wholly owned subsidiary of WuXi AppTec, WuXi NextCODE offers its global clients fully integrated turnkey solutions for genomic medicine, from CLIA sequencing to bioinformatics, clinical interpretation, and diagnostic test development and delivery. WuXi NextCODE's technology is being used to analyze and manage whole-genome data on 350,000 people, more than any other system in use today.

Fudan led the establishment of CICGD in 2012 under the auspices of the Higher Education Institution Innovation Improvement Plan implemented by China's Ministry of Education and Ministry of Finance. The CICGD brings together several other world-renowned Chinese research institutions, including Shanghai Jiaotong University, Nanjing University, Zhongshan University, Central South University, the Shanghai Institutes for Biological Sciences, the Institute of Genetics and Developmental Biology, and the Beijing Institute of Genomics. Collectively, these institutions are dedicated to researching scientific questions in genetics and developmental biology as well as evaluating their impact on human health.

"We are delighted to partner with Fudan University, a top university and a pillar of genetic research in China, to promote genomics research and its applications," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "The partnership integrates WuXi's world-leading genomics platform with China's leading research and innovation capabilities to bring the latest technological and medical advances closer to patients in China and around the world."

"WuXi NextCODE's genome analysis technology is the best in the world, and it underpins the most advanced and largest-scale genomics research currently being conducted," said Dr. Li Jin, Director of CICGD and Vice President of Fudan University. "Fudan's partnership with WuXi will turn Shanghai into a premier global innovation center for human genomics. We are thrilled at the opportunity to work with WuXi's unrivalled genomic data management and clinical data analysis system, which will undoubtedly enhance CICGD's research and application capabilities in genetics and genomics."

SHANGHAI, May 22, 2015 /PRNewswire/ -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

Ambrx is a clinical-stage biotechnology company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates. The company's proprietary technology platforms enable attachment of pharmaceutically active molecules to specific sites within proteins more precisely than prior generations of bio-conjugates and with precision similar to that used to design small-molecule drugs. Ambrx has developed a pipeline of novel product candidates that include antibody-drug conjugates, or ADCs, bi- and multi-specific drug conjugates, and long-acting therapeutic proteins.

ADCs are expected to be one of the most important areas of monoclonal antibody development in the next decade, especially in targeted therapies for oncology, an area where Ambrx has a strong internal pipeline. The company's most advanced internally developed product is ARX788, a site-specific ADC targeting Her2-positive breast cancer that Ambrx expects to begin clinical trials on in 2015.

In addition to its internal pipeline, Ambrx collaborates with leading pharmaceutical companies, including Bristol-Myers Squibb, Merck, Eli Lilly, and Agensys. Ambrx's most advanced collaboration product candidate in human health is ARX618, a long-acting fibroblast growth factor 21 for type 2 diabetes, for which collaboration partner Bristol-Myers Squibb is conducting Phase 2 clinical trials in the United States. To date, collaborations have provided Ambrx with over $200 million in funding and have the potential to provide milestone payments and royalties on the sale of collaboration products.

Chairman of Fosun Pharma Mr. Chen Qiyu said, "This joint acquisition will result in great synergy with Fosun Pharma's current R&D system and platform. Fosun Pharma has an internationalized R&D deployment in place with strong R&D capability. It has established an interactive and integrated R&D system in Shanghai, Chongqing, and San Francisco, focusing on the R&D of macromolecular biopharmaceutical drugs, especially monoclonal antibodies. Under the help of Fosun Pharma, Ambrx's business expanding in China will enable Chinese patients to get faster access to innovative therapeutic drugs."

"We are pleased to join the Consortium to acquire Ambrx, a top-tier innovative biologics company with a cutting-edge second-generation ADC technology platform," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC platform and biologics development capabilities to better serve our global customers."

"We are excited to advance Ambrx's development programs and technologies with members of the Consortium," said Ambrx's CEO and President Lawson Macartney, Ph.D., FRCPath. "I would like to thank Ambrx's employees and partners for their dedicated efforts to bring important new therapies to patients."

BMO Capital Markets Corp. is acting as exclusive financial advisor and Latham & Watkins is acting as legal advisor to Ambrx in connection with this transaction. Haynes and Boone is acting as legal advisor to the Consortium in connection with this transaction.

HANGHAI, May 21, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the launch of LabNetwork (www.labnetwork.com). LabNetwork is a global e-Commerce platform for connecting buyers and sellers of research chemicals and reagents. Backed by WuXi's world-class expertise in chemistry R&D, sourcing, and quality control, LabNetwork will bring trusted, novel, and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide.

For researchers and chemists, LabNetwork provides sophisticated web and mobile tools that allow customers to search for compounds by either keyword or chemical structure, with intelligent ranking of results. With a platform built for speed and ease of use, buyers can make informed decisions based upon cost, speed of delivery, and product quality. LabNetwork features multi-language and multi-currency shopping capabilities, including quotation, ordering, and tracking.

Suppliers will be able to leverage LabNetwork's customizable platform, global warehousing, logistics, and compliance solutions to reach new customers and markets. LabNetwork provides capabilities to increase distribution channels, author Safety Data Sheets in over 45 languages, and develop Global Harmonized System compliant labels.

LabNetwork currently offers nearly 300,000 research chemicals from a dozen quality suppliers, including the WuXi catalog of over 112,000 screening compounds, building blocks, and other off-the-shelf compounds. Many more supplier catalogs will be added in the coming weeks and months.

"LabNetwork will be a catalyst to enable more efficient and cost-effective research," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This initiative is an important step in advancing WuXi's mission to broaden our service offerings and enable scientists anywhere in the world to leverage the LabNetwork platform to conduct their research more efficiently and cost effectively."

• Net Revenues Increased 22.7% Year Over Year to $180.0 Million
• Non-GAAP Diluted Earnings Per ADS Increased 17.5% Year Over Year to $0.36

Management Comment

"WuXi achieved strong revenue growth in the first quarter and continued to invest aggressively to seize opportunities and sustain long-term revenue growth," said Dr. Ge Li, Chairman and CEO.  "Total company revenue grew 22.7% year over year.  Laboratory Services revenue grew 20.6%, led by strong performances in chemistry, toxicology, and analytical development in China and in cell therapy manufacturing in the United States.  We have invested behind these businesses with our acquisition of XenoBiotic last year and ongoing construction of two cell therapy manufacturing facilities.

"While we expect continued strong growth from Laboratory Services, small-molecule manufacturing and biologics will be our key growth businesses over the next few years, and both performed very well in the quarter.  Small-molecule manufacturing revenue grew 14.8%, driven by a solid pipeline of research and commercial manufacturing projects.  Biologics revenue grew 74.6% in the quarter due to increasing demand for both development and manufacturing services.  We are building major new facilities for long-term growth in these two businesses.

"Our success over the past 14+ years has come from aggressively investing where we see significant market opportunities and favorable trends," Dr. Li concluded.  "Today we continue to make aggressive investments in exciting new areas such as genomics and bioinformatics, mobile technologies, and China healthcare initiatives.  We are encouraged by the long-term potential of these investments, although we may not see returns from them quickly."

Full-Year 2015 Financial Guidance

WuXi PharmaTech provides the following full-year 2015 financial guidance:

• Total net revenues of $790-$800 million, the same as previous guidance
• GAAP diluted earnings per ADS of $1.21-$1.26^ab, compared to previous guidance of $1.31-$1.36
• Non-GAAP diluted earnings per ADS of $1.73-$1.78^b, the same as previous guidance
• Capital expenditures of $180-$200 million, the same as previous guidance

Second-Quarter 2015 Financial Guidance

WuXi PharmaTech provides the following second-quarter 2015 financial guidance:

• Total net revenues of $194-$196 million
• GAAP diluted earnings per ADS of $0.25-$0.27^b
• Non-GAAP diluted earnings per ADS of $0.38-$0.40^b

SHANGHAI, April 30, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE:WX), a leading global contract R&D services provider, today announced that its board of directors has received a preliminary non-binding proposal letter, dated April 29, 2015, from a consortium (the "Consortium") led by Dr. Ge Li (the "Chairman"), founder, chairman and chief executive officer of the Company, and Ally Bridge Group Capital Partners ("ABG") that proposes a transaction (the "Transaction") involving the acquisition of all outstanding shares of the Company not already owned by members of the Consortium for $46.00 in cash per American Depositary Share ("ADS", each ADS representing eight ordinary shares), or $5.75 in cash per ordinary share. ABG is a global healthcare-focused investment group, founded and led by Mr. Frank Yu (formerly a Managing Director of Goldman Sachs and Och-Ziff Capital).

According to the proposal letter, the Consortium will form an acquisition company for the purpose of implementing the Transaction, and the Transaction is intended to be financed with a combination of debt and equity capital. The proposal letter also states that the Chairman and ABG have agreed to work together exclusively in pursuing the Transaction. A copy of the proposal letter is attached hereto as Exhibit A.

The Company's Board of Directors will form a special committee comprising independent directors of the Company (the "Special Committee") to consider the proposed transaction. The Special Committee is expected to be authorized to retain independent advisors, including a financial advisor and legal counsel, to assist it in its work.

No decisions have been made by the Special Committee with respect to the Company's response to the Transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

SHANGHAI, April 30, 2015 /PRNewswire/ -- WuXi Biologics, a wholly owned subsidiary of WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that construction has begun on a new $150 million biologics manufacturing facility in Wuxi city.

When complete, this new facility will be the largest mammalian cell culture manufacturing facility using disposable bioreactors in the world. It will also be the largest biologics manufacturing facility of any kind in China. This added capacity will support WuXi's strong biologics manufacturing pipeline in the near term and enable WuXi to maintain its position as the premier biologics manufacturer in China as well as a leading player worldwide.

The new facility to be completed by January 2017 will house fourteen 2000L disposable bioreactors for fed-batch cell culture and two 1000L bioreactors for perfusion runs. The facility will also be built to run advanced continuous or semi-continuous manufacturing processes in addition to traditional fed-batch and perfusion modes.

This facility further expands WuXi's already extensive biologics manufacturing capabilities. In August 2012, WuXi completed state-of-the-art biologics clinical drug substance and drug product manufacturing facilities in Wuxi city, the first in China that met cGMP standards of the United States, the European Union, and China. Since then, the facilities have ramped up quickly to produce clinical supplies for the US, EU, China and other markets. In March 2014, the drug substance facility received the honorable mention "facility-of-the-year" award by International Society For Professional Engineering (ISPE), a first for China.

"Investment in this state-of-the-art biologics commercial facility of the future is another milestone for WuXi Biologics," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This project continues to strengthen WuXi's capabilities in integrated biologics discovery, development, and manufacturing services. We maintain the highest quality standards to expedite global development of biologics for both international clients and Chinese companies."

SHANGHAI; CAMBRIDGE, Mass.; and MOUNTAIN VIEW, Calif., April 22, 2015 /PRNewswire/  WuXi PharmaTech (Cayman) Inc. (NYSE: WX), whose leading open-access R&D capability and technology platform serves the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary WuXi NextCODE Genomics, which provides the most proven system for using sequence data to better diagnose and treat disease, and DNAnexus, the leader in cloud-based genome informatics and data management, have formed a strategic alliance that aims to accelerate the use of genomics to benefit patients worldwide.

Now available via a single platform are the sequence data analysis suite that has analyzed more genomes than any other; pioneering Silicon Valley genomics cloud technology; and global, open-access drug discovery and development capabilities serving the life science industry:

• Bringing cloud-based genomics to China and Chinese genomics to the world
• Speeding the development and delivery of sequence-based diagnostics worldwide
• Expanding research with collaborations and datasets of unprecedented scope and size
• Streamlining the development of personalized medicine and companion diagnostics
• Leveraging WuXi's leading genomics and R&D through DNAnexus's global cloud

"This strategic investment and partnership bring together the world's best technologies to enable any company or institution to leverage the full power of genomics and our R&D capabilities at any time, from anywhere," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "By connecting through a compliant cloud everything from CLIA sequencing to drug discovery and development to companion diagnostics, we are empowering clinicians, institutions and life science companies to use genomics to benefit patients more globally and effectively than ever before."

"This alliance with DNAnexus will fuel innovation across the science and business of genomics and make our collective capabilities even more valuable to the range of our customers on four continents," said Hannes Smarason, Chief Operating Officer of WuXi NextCODE. "We see this transforming the way large-scale sequence data is applied, underpinning virtual diagnostics enterprises, breakthroughs in rare disease and the rapid advance of more targeted, personalized medicine."

"Our customers are global in scope, and we're teaming with WuXi NextCODE to extend the power and geographic reach of our cloud solution to support our partners' efforts," said Richard Daly, CEO of DNAnexus. "China has 20% of the world's sequencing capacity and is a pillar of cutting-edge science worldwide. The DNAnexus platform enables research, drug development and clinical diagnostic testing worldwide, and this alliance and investment allows us to expand our global network for genomic medicine."

With WuXi NextCODE's unique genomic database model and clinical and research interfaces directly available on the DNAnexus cloud, users will be able to store and interpret their sequence data and collaborate with colleagues around the world through one platform. The companies will also provide and host the same platform and capabilities within China, in full compliance with local regulations. Users will be able to use their genomic data seamlessly in tandem with the open-access capability and technology platform that WuXi offers to the global pharmaceutical, biopharmaceutical and medical device industry.

SHANGHAI; CAMBRIDGE, Mass.; and MOUNTAIN VIEW, Calif., April 22, 2015 /PRNewswire/  WuXi PharmaTech (Cayman) Inc. (NYSE: WX), whose leading open-access R&D capability and technology platform serves the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary WuXi NextCODE Genomics, which provides the most proven system for using sequence data to better diagnose and treat disease, and DNAnexus, the leader in cloud-based genome informatics and data management, have formed a strategic alliance that aims to accelerate the use of genomics to benefit patients worldwide.

Now available via a single platform are the sequence data analysis suite that has analyzed more genomes than any other; pioneering Silicon Valley genomics cloud technology; and global, open-access drug discovery and development capabilities serving the life science industry:

• Bringing cloud-based genomics to China and Chinese genomics to the world
• Speeding the development and delivery of sequence-based diagnostics worldwide
• Expanding research with collaborations and datasets of unprecedented scope and size
• Streamlining the development of personalized medicine and companion diagnostics
• Leveraging WuXi's leading genomics and R&D through DNAnexus's global cloud

"This strategic investment and partnership bring together the world's best technologies to enable any company or institution to leverage the full power of genomics and our R&D capabilities at any time, from anywhere," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "By connecting through a compliant cloud everything from CLIA sequencing to drug discovery and development to companion diagnostics, we are empowering clinicians, institutions and life science companies to use genomics to benefit patients more globally and effectively than ever before."

"This alliance with DNAnexus will fuel innovation across the science and business of genomics and make our collective capabilities even more valuable to the range of our customers on four continents," said Hannes Smarason, Chief Operating Officer of WuXi NextCODE. "We see this transforming the way large-scale sequence data is applied, underpinning virtual diagnostics enterprises, breakthroughs in rare disease and the rapid advance of more targeted, personalized medicine."

"Our customers are global in scope, and we're teaming with WuXi NextCODE to extend the power and geographic reach of our cloud solution to support our partners' efforts," said Richard Daly, CEO of DNAnexus. "China has 20% of the world's sequencing capacity and is a pillar of cutting-edge science worldwide. The DNAnexus platform enables research, drug development and clinical diagnostic testing worldwide, and this alliance and investment allows us to expand our global network for genomic medicine."

With WuXi NextCODE's unique genomic database model and clinical and research interfaces directly available on the DNAnexus cloud, users will be able to store and interpret their sequence data and collaborate with colleagues around the world through one platform. The companies will also provide and host the same platform and capabilities within China, in full compliance with local regulations. Users will be able to use their genomic data seamlessly in tandem with the open-access capability and technology platform that WuXi offers to the global pharmaceutical, biopharmaceutical and medical device industry.

SHANGHAI, April 2, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary SynTheAll Pharmaceutical Co. Ltd. ("STA") has received approval from the National Equities Exchange and Quotations ("NEEQ") in China to list its shares on the New Third Board, the over-the-counter (OTC) stock exchange in China. STA shares will be listed beginning April 3, 2015. WuXi does not currently plan to issue new STA stock to the public immediately upon listing. In March 2015, following receipt of required government approvals, WuXi agreed to sell a 5.55% stake in STA stock to members of STA management and WuXi management at a price based on a third-party appraisal of the STA equity value. This sale will be settled in early April for approximately $28 million in total cash consideration, with WuXi recognizing a related gain on the sale in the second quarter of 2015. Two thirds of the shares purchased by the management employees are subject to a lock-up, with 1/3 available for sale on the first anniversary of the listing date and another 1/3 available for sale on the second anniversary of the listing date.

STA provides process chemistry services and manufactures small-molecule advanced intermediates and APIs for customer use in preclinical and clinical trials and for marketed small-molecule drugs. Its operations are located in the Waigaoqiao Free Trade Zone and Jinshan, both in Shanghai, and in Changzhou. STA does not include WuXi's biologics manufacturing business. STA's business is significantly more capital intensive than WuXi's laboratory services business and is in the process of building new facilities in Changzhou to increase its production capacity. STA filed this application to list on the New Third Board late last year to allow the flexibility to raise capital eventually from the Chinese capital markets to fund its future growth and to pursue potential mergers and acquisitions.

The New Third Board was established by the State Council in January 2013 as a national OTC stock exchange to supplement trading activities on the Shanghai and Shenzhen stock exchanges, including the related Growth Equity Market (GEM) exchanges. China's GEM exchanges provide for trading of stock of growth companies that do not otherwise satisfy the requirements for listing on the main Shanghai and Shenzhen stock exchanges. The New Third Board provides a pricing mechanism for valuing a company's stock. Policies are currently expected to be introduced in the second half of 2015 to enable NEEQ-registered companies to transfer to the GEM exchanges.

SHANGHAI, March 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration (CFDA).

In September 2012, MedImmune, the global biologics research and development arm of AstraZeneca, and WuXi AppTec formed the joint venture WuXi MedImmune Biopharmaceutical Co. Limited to develop and commercialize MEDI5117, a novel, investigational, long-acting monoclonal antibody for autoimmune and inflammatory diseases, the first such collaboration in China between a global company and a Chinese company to develop novel biologics. WuXi AppTec completed all CMC, nonclinical, and clinical sections of the dossier, and the wholly owned subsidiary of the joint venture filed an IND for it with the Jiangsu provincial FDA as a Class 1 therapeutic biologic in December 2014. WuXi AppTec's biologics and pre-clinical facilities in Shanghai, Suzhou, and Wuxi passed the Jiangsu FDA's onsite inspections in January 2015. The IND application has now been entered into the system of the CFDA for technical review. WuXi AppTec will continue to provide manufacturing for the program at its state-of-the-art biologics facilities, the first in China to meet cGMP standards of the United States, the European Union, and China, as well as provide local regulatory, pre-clinical, and clinical trial support.

"We are very pleased that our collaboration with MedImmune has advanced this important novel class 1 biologic on schedule," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "WuXi's capabilities in integrated biologics discovery, development, and manufacturing offer a global platform with the highest quality standards. This initiative showcases WuXi's capabilities as a gateway for developing novel biologics in China."

SHANGHAI, March 12, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, announced today that it will soon begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies. CAR T cells are T cells harvested from a patient's body, engineered to target specific cancers, and then reintroduced into the body.

The new facility will become WuXi's third cell therapy manufacturing facility when it becomes operational by mid-2016. It will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements. Specifically, the new facility will provide manufacturing capability and capacity to meet the rapidly expanding demand for clinical studies and commercial supply. The new facility will expand upon WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility, as well as a 45,000-square-foot facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015. By 2016, WuXi's available manufacturing capacity in the U.S. of 206,000 square feet would help meet the anticipated market needs of clinical and commercial production for cell-therapy companies. These facilities will complement the company's current fully integrated facility for biological safety and lot release testing in Philadelphia.

"Cell therapies like CAR T cells offer important new treatment options for cancer patients, and WuXi aims to be at the forefront of this area of providing our partners with cutting-edge cGMP manufacturing capabilities and capacities," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

Fourth-Quarter 2014 Financial Results

• Net Revenues Increased 21.3% Year Over Year to $190.6 Million 
• Non-GAAP Diluted Earnings Per ADS Increased 4.1% Year Over Year to $0.55

Management Comment

"We completed a strong 2014 with a very good fourth quarter," said Dr. Ge Li, Chairman and CEO. "Full-year 2014 revenue growth of 16.6% and fourth-quarter 2014 revenue growth of 21.3% both exceeded our guidance. Our revenue growth was broad-based, with both Laboratory Services and Manufacturing Services achieving record revenues both in the fourth quarter and the full year. We also made investments in 2014 in new capabilities, including talent, new laboratories, and technologies, particularly in manufacturing, biologics, genomics, R&D, sales and marketing, and information technology, to sustain our business growth.

"We continue to invest to strengthen our core businesses, particularly in expansion of capacity," Dr. Li continued. "Capital spending will be in the range of $180-$200 million in 2015. We expect to complete construction of new small-molecule manufacturing facilities in Changzhou in late 2015/early 2016. We will begin construction of commercial-scale biologics manufacturing facilities in Wuxi city adjacent to our existing clinical facilities in 2015 and complete construction in late 2016. Each of these manufacturing facilities will cost nearly $150 million and support strong growth in demand in these businesses. Two new cell therapy manufacturing facilities in Philadelphia, to be completed in 2015 and 2016, respectively, will cost an additional $40 million in total and expand our capabilities in this rapidly developing field.

"We are also investing aggressively in 2015 in new businesses to seize opportunities for further growth. We have been good at planting seeds when we see emerging business opportunities, and we don't hesitate to invest to capture growing demand and to capitalize on market trends. We did so in the past few years in building our small-molecule manufacturing business and our biologics business in China by investing aggressively. Now we are getting strong growth and returns from these investments. We are very excited and confident about our new investments in genomics/bioinformatics, clinical diagnostics, e-commerce, cell therapy manufacturing, e-health solutions, and other emerging areas with tremendous potential. These investments are expected to reduce 2015 diluted earnings per share by about 26 cents per share and to earn strong returns in future years.

"New technologies, emerging markets, and global connectivity will profoundly change the practice of medicine in the 21^st century," Dr. Li concluded. "Genomic medicine will fundamentally change how doctors treat patients and how patients access better healthcare solutions. The newly established WuXi NextCODE Genomics is already at the forefront of developing products and services to meet such a powerful paradigm shift. We are equally excited about the future of the China healthcare market. WuXi is uniquely positioned to bring western innovation to China with our comprehensive R&D capabilities, superior access to technology, extensive China healthcare know-how, and a 15-year track record of accomplishment. We are investing in our e-commerce platform for reagent sales and custom synthesis via Labnetwork.com and the WuXi V-Lab App, respectively. We expect our new investments will augment the continuing strong performance of our core businesses to propel our growth for years to come."

Full-Year 2015 Financial Guidance

WuXi PharmaTech provides the following full-year 2015 financial guidance:

• Total net revenues of $790-$800 million 
• GAAP diluted earnings per ADS of $1.31-$1.36 
• Non-GAAP diluted earnings per ADS of $1.73-$1.78 
• Capital expenditures of $180-$200 million 

First-Quarter 2015 Financial Guidance

WuXi PharmaTech provides the following first-quarter 2015 financial guidance:

• Total net revenues of $173-$175 million 
• GAAP diluted earnings per ADS of $0.20-$0.22 
• Non-GAAP diluted earnings per ADS of $0.30-$0.32 

SHANGHAI, February 28, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355). The FDA designates a drug as a breakthrough therapy if it is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. It is being developed by TaiMed Biologics for the treatment of HIV/AIDS infection. Clinical-trial supplies of ibalizumab were manufactured at WuXi's biologics manufacturing facilities. WuXi will work closely with TaiMed in additional clinical-supply manufacture and process validation to assist TaiMed's anticipated submission of a rolling BLA application. If approved, ibalizumab would be the first biologic product manufactured in China to be launched in the U.S. market.

"We commend our partner TaiMed for this significant regulatory action," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This is the fourth WuXi-manufactured product to be so designated, reflecting the high quality of the molecules that we choose to work on. We will give TaiMed our full support as they advance this promising product candidate through regulatory review."

SHANGHAI, February 17, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced that it has entered into a syndicated loan facility to borrow up to $165 million from a consortium of banks in Asia led by Citibank. The borrowing will incur interest at a rate of LIBOR plus 2.89%, including all expenses, and will be repaid in four installments over 18-36 months.

"This new loan agreement provides WuXi with the resources to invest in several new business opportunities without impacting the strong growth of our current operations," said Edward Hu, Chief Financial Officer of WuXi PharmaTech. "To meet the growing demand of our services, we are building:

• small-molecule manufacturing facilities in Changzhou that will double our current capacity by late 2015 or early 2016 and that will cost nearly $150 million
• biologics commercial manufacturing facilities in Wuxi city that will also cost nearly $150 million and be completed by late 2016
• two cell-therapy manufacturing facilities in Philadelphia that will cost about $40 million

Our capital spending was approximately $110 million in 2014 and will be approximately $200 million in 2015. We have used cash in 2014 and 2015 to make two acquisitions--XenoBiotic Laboratories, Inc., for $37.5 million and NextCODE Health for $65 million."

"The new debt facility will enable us to make the investments necessary for our company to achieve its full potential," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "While continuously strengthening our existing capabilities, we also see new investment opportunities in the rapidly growing China healthcare market. We need to invest aggressively to extend our research and development capabilities to hospitals, doctors, and patients to capture many of these exciting opportunities."

SHANGHAI, Jan. 30, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced today that SynTheAll Pharmaceutical Co., Ltd. (STA), WuXi's small-molecule manufacturing subsidiary, has won a 2015 CMO Leadership Award, which is presented by Life Science Leader magazine based on research conducted by Nice Insight. STA has won in the perception category of Reliability in the company category of Big Pharma. The award is based on the survey responses of more than 2,300 pharmaceutical and biopharmaceutical professionals. WuXi and STA also received a CMO Leadership Award for Quality in 2012.

"On behalf of 1,500 highly dedicated employees at STA, I am very pleased to accept this award," said Dr. Minzhang Chen, Senior Vice President of WuXi PharmaTech and General Manager of STA. "Every day we at STA strive to provide our customers with the highest quality of services across our integrated small-molecule API development and manufacturing platform from process chemistry to research and commercial manufacturing."

STA continues to invest in new capabilities and capacity. Its high-potency development and GMP labs in Shanghai began operations in 2014. In collaboration with its partners, STA is in the process of building its continuous processing and biocatalysis technology platforms. Its new Changzhou campus is currently under construction. Upon the completion of this $140 million investment, STA's capacity in both process chemistry and research and commercial manufacturing will double to meet the growing demand for its services.

"I am especially pleased that STA received this recognition from our most important audience--our customers," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This is the second time we have won this award, and it reflects our long-time commitment to our partners worldwide in the discovery, development, and commercialization of new medicines to benefit the world's patients."

SHANGHAI , January 9, 2015 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has updated its 2014 financial guidance. The company expects to achieve total revenues for full-year 2014 of approximately $674 million, compared to previous guidance of $670-672 million. The company expects to achieve diluted EPS of approximately $1.87 (non-GAAP) and approximately $1.56 (GAAP), compared to previous guidance of 1.83-1.86 (non-GAAP) and $1.55-1.58 (GAAP). These preliminary 2014 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting, and audit processes. The company plans to report its fourth-quarter and full-year 2014 financial results and to provide 2015 financial guidance in March 2015.

SHANGHAI, January 9, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announces that it has acquired NextCODE Health, a leading genomic analysis and bioinformatics company with operations in the United States and Iceland, for $65 million in cash. WuXi plans to merge NextCODE Health and WuXi's Genome Center into a new company to be named WuXi NextCODE Genomics. The business will be headquartered in Shanghai, with operations in Cambridge, Massachusetts, and Reykjavik, Iceland. The leadership of WuXi NextCODE Genomics will include Dr. Ge Li as CEO, Edward Hu as CFO, Hannes Smarason as COO, Dr. Jeffrey Gulcher as CSO, Dr. Hongye Sun as CTO, and Dr. Hakon Gudbjartsson as VP Informatics.

NextCODE Health was spun out from deCODE genetics after the latter was acquired by Amgen in December 2012. Founded in 1996, deCODE genetics is a global leader in analyzing and understanding the links between the genome and disease susceptibility. Using its unique expertise and population resources in Iceland, deCODE genetics has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer. In October 2013, NextCODE Health announced that it had obtained from Amgen a five-year exclusive license for sequence-based clinical diagnostic applications using technology developed by deCODE genetics.

NextCODE Health has developed the world's leading genome sequence analysis platform and the most efficient database architecture, enabling clinicians and researchers around the globe to use the full power of next-generation sequencing data to better diagnose and treat diseases. The company's solutions combine the only whole genome analysis system developed at population scale with access to the largest clinical genetics reference database in the world. These capabilities give clinicians and researchers the ability to store, visualize, and analyze all of their genetic data at base-by-base resolution, in real time, from any browser; to collaborate with other clinicians and researchers; and thereby to solve more medical cases more efficiently.

The WuXi Genome Center was established in 2011 to provide next-generation sequencing solutions to academics, the life science industry, and medical institutions to advance personalized medicine. By integrating with WuXi AppTec's full range of discovery and development services for the biopharmaceutical industry, the WuXi Genome Center provides a complete solution for drug development projects from target discovery and preclinical and clinical development to personalized medicine. The center meets international clinical standards and is the only CLIA-certified clinical genomics laboratory in China. WuXi Genome Center has ten Illumina HiSeq X sequencing machines in operation. In addition to offering sequencing services, WuXi's genomics lab also provides assay development, validation, and testing services.

This acquisition lays the groundwork for the creation of an integrated global enterprise with unique advantages for applying genomics to medicine. It broadens and enhances WuXi's existing genomic laboratory services for biopharmaceutical research and clinical development, as well as NextCODE's unique capabilities in genome analysis. It provides global commercial customers of both entities with comprehensive genomic and bioinformatic capabilities, from CLIA-certified whole genome and whole exome sequencing to the analysis and interpretation of that sequencing data necessary to provide effective diagnosis and treatment.

This acquisition also represents an important step forward in WuXi's development. For the first 14 years of its history, WuXi has served companies in the worldwide pharmaceutical, biotechnology, and medical device industries as they discover and develop new healthcare products. The acquisition will enable WuXi to broaden its customer base to doctors and patients. This is very important for WuXi's vision to enable anyone and any company to discover and develop healthcare products and services to benefit patients.

"With the huge unmet medical needs in diseases with a genetic component and the rapid advances in genomics and bioinformatics, now is the right time for WuXi to make a strategic investment in this field, and NextCODE is the right partner," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This new venture of WuXi NextCODE Genomics will create important new genomic and bioinformatic products and services to help make personalized treatment and medicine a reality. It will also enable doctors to provide better treatments to patients."

"With this transaction, WuXi and NextCODE will deploy the unique advantages of their combined platform in virtually every major application of genomics worldwide," said Hannes Smarason and Jeffrey Gulcher, co-founders of NextCODE Health. "In WuXi, we have a superior partner with strengths, including CLIA-certified sequencing and leading global pharmaceutical customers with a strong need for companion diagnostics, that are highly complementary to those of NextCODE. Together, WuXi and NextCODE have the technology, vision, and resources to be a leader in the sequencing revolution for the benefit of patients and for the advancement of medicine around the world."

SHANGHAI, December 5, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced today that it has won the SCRIP Award in the category of "Best Company in an Emerging Market." This award recognizes the rapid growth, significant accomplishments, and increasing global presence achieved by WuXi AppTec in 2014. This is the first time a China-based company has won this SCRIP Award. WuXi AppTec was presented with the award at the 10th Annual SCRIP Awards ceremony held in London on December 3, 2014.

Established in 2005 by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech sectors, the annual SCRIP Awards acknowledge the most significant achievements of outstanding companies worldwide.

"We are greatly honored to receive this prestigious industry award and to play a role in helping our partners develop innovative products through our open-access capability and technology platform," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This award belongs to our employees and collaborative partners around the globe, whose efforts, ingenuity and dedication are making a real difference in the quest to discover and develop new medicines for patients."

SHANGHAI, December 4, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary SynTheAll Pharmaceutical Co. Ltd. ("STA") has submitted an application to the National Equities Exchange and Quotations ("NEEQ") in China to list on the New Third Board, the over-the-counter (OTC) stock exchange in China.

STA provides process chemistry services and manufactures small-molecule advanced intermediates and APIs for customer use in preclinical and clinical trials and for marketed small-molecule drugs. Its operations are located in the Waigaoqiao Free Trade Zone and Jinshan, both in Shanghai, and in Changzhou. STA does not include WuXi's biologics manufacturing business. STA recorded revenues of $142.1 million for full-year 2013 and of $127.9 million for the first nine months of 2014. STA is significantly more capital intensive than WuXi's laboratory services business and is in the process of building new facilities in Changzhou to increase its production capacity. STA filed this application to list on the New Third Board to allow the flexibility to raise capital eventually from the Chinese capital markets to fund future growth.

China is undergoing capital market reform. The New Third Board was established by the State Council in January 2013 as a national OTC stock exchange to supplement trading activities on the Shanghai and Shenzhen stock exchanges, including the related Growth Equity Market (GEM) exchanges. China's GEM exchanges provide for trading of stocks of growth companies that do not otherwise satisfy the requirements for listing on the main Shanghai and Shenzhen stock exchanges. The New Third Board provides a pricing mechanism for valuing a company's stock. As of November 25, 2014, there were 1,350 companies listed on the New Third Board and 732 companies with applications in the review process for listing on the New Third Board. Policies are currently expected to be introduced in mid-2015 to enable NEEQ-registered companies to transfer to the GEM exchanges. WuXi does not currently plan to issue STA stock to the public immediately upon listing on the New Third Board.

There can be no assurances that STA will be registered on the New Third Board or that any IPO will occur. Any IPO and registration/listing of STA in China is subject to, among other things, market and business conditions, adoption of appropriate rules by the China Securities Regulatory Commission and the applicable stock exchanges, and STA satisfying these rules and other registration/listing and offering requirements.

Third-Quarter 2014 Financial Results

• Net Revenues Increased 18.3% Year Over Year to $173.6 Million
• Non-GAAP Diluted Earnings Per ADS Increased 13.8% Year Over Year to $0.54

SHANGHAI, October 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced the establishment of a representative office in the Tel Aviv area of Israel.

The new office will promote WuXi's broad platform of integrated R&D services to local customers. It will also collaborate with Pontifax, a leading healthcare-dedicated venture capital firm based in Israel, to invest in promising technologies in Israel, particularly those that can potentially advance WuXi's capabilities.

"We welcome WuXi's presence in Israel and believe the new representative office will be mutually beneficial to WuXi and the Israeli biotech industry," said Tomer Kariv, CEO of Pontifax.

"We are excited to establish a presence in Israel and to contribute to one of the most dynamic healthcare innovation ecosystems in the world," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "We value the expertise that Pontifax has developed in Israel's biotech industry and look forward to working closely with them to help many of their portfolio companies and other startup companies. This step advances WuXi's mission of helping entrepreneurs in the global life sciences industry to realize their dreams of developing innovative products to benefit the world's patients."

SHANGHAI, October 24, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients.

"We commend TaiMed's great progress in advancing this important life-saving therapy," said Dr. Ge Li, Chairman and CEO of WuXi. "This is the first biologic manufactured in China to receive Orphan Drug Designation, a historic milestone for TaiMed, for WuXi, and also for China."

CAMBRIDGE, Mass. and SHANGHAI, Oct. 22, 2014 /PRNewswire/--  Foundation Medicine, Inc. (NASDAQ:FMI) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced a collaboration to offer Foundation Medicine's comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China.

Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine's FoundationOne� assay at the WuXi Genome Center inShanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China.  Financial terms of the collaboration are not being disclosed.

"China is poised to become the second-largest pharmaceutical market within the next few years," said Dr. Ge Li, chairman and chief executive officer of WuXi. "WuXi has seen rapidly increasing demand for molecular profiling services from biopharmaceutical companies as they scale up R&D operations and early development activities in the region.  We are pleased to partner with Foundation Medicine, the recognized global leader in comprehensive genomic profiling and a trusted partner of our customers, to provide best-in-class genomic testing to support targeted oncology therapeutic development inChina."

"WuXi is the recognized leader in providing high-quality R&D services in China to the biopharmaceutical industry," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine.  "The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China.  WuXi's leadership position in Chinamakes WuXi an ideal partner as Foundation Medicine expands its global reach to support targeted drug development and clinical entry into this rapidly growing market."

SHANGHAI, October 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (WuXi) (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, announced today that it has acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of successful operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. Financial terms were not disclosed. The transaction closed on September 30, 2014, and is expected to be neutral to WuXi's 2014 diluted EPS and accretive to WuXi's 2015 diluted EPS on a non-GAAP basis.

The acquisition bolsters WuXi's Laboratory Testing Division (LTD) in bioanalytical and DMPK/ADME services, particularly in studies of radio-labeled compounds, while gaining access to new agricultural and animal health customers. The resulting expansion and enhancement of WuXi's integrated service portfolio will accelerate the growth of LTD's business and further strengthen WuXi's position as a leading research and development service provider to the pharmaceutical and biotech industries. This acquisition expands LTD's presence in North America, provides greater flexibility in service and support options for our North American customers, and presents the opportunity for further expansion.

XBL has 150 employees and operates a 45,000-square-foot research center in Plainsboro, New Jersey, and a 36,000-square-foot facility in Nanjing, China. The company is FDA- and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances, and AAALAC-accredited.

"My colleagues and I are very excited to join WuXi, a global leader in providing drug discovery and development services to the global biopharmaceutical industry," said Dr. Jinn Wu, President and Chief Executive Officer of XBL, who has been appointed Vice President and Chief Scientific Officer of LTD. "We will continue to provide our services to our current clients while also offering expanded services to WuXi's clients."

"We are very pleased to have XBL join the WuXi team," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi. "Dr. Wu has spent the past 27 years building a solid organization and reputation within the industry. This business combination is an important step in WuXi's development of a comprehensive, integrated platform of R&D services to help our customers discover and develop drugs more efficiently and cost-effectively."

SHANGHAI, August 18, 2014 /PRNewswire/ -- WuXiPharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that a manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA) passed an FDA inspection in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug.

This represents the first FDA inspection of STA's facilities for the manufacture of an API. Last year, STA's manufacturing operations passed an inspection by the FDA for the manufacture of an advanced intermediate.

STA's integrated platform of services, extending from process research to research manufacturing to commercial manufacturing, helps the company's clients move their new chemical entities through preclinical and clinical development to global commercial launch.

"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, Chairman and CEO of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."

 Second-Quarter 2014 Financial Results

• Net Revenues Increased 14.8% Year Over Year to $163.4 Million
• Non-GAAP Diluted Earnings Per ADS Increased 5.2% Year Over Year to $0.49

"WuXi PharmaTech had another solid performance in the second quarter," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We achieved record quarterly revenues, led by small-molecule manufacturing and biologics. Our revenue growth was broad-based, with 19.3%, 14.2%, and 9.6% year-over-year growth in Manufacturing Services, China Lab Services, and U.S. Lab Services, respectively, and we exceeded our second-quarter guidance in revenues.

"We also had a good quarter in profitability, exceeding our second-quarter guidance for non-GAAP diluted EPS and achieving the top of our guidance range for GAAP diluted EPS," Dr. Li continued. "Gross margin in the second quarter reflected year-over-year improvement of more than one full percentage point, driven by productivity initiatives, effective cost control, and the favorable impact of a depreciated RMB. We are using our free cash flow to reinvest in our business as we build new capabilities in manufacturing, biologics, genomics, cell therapy, sales and marketing, information technology, and other areas. We also purchased $66 million of our stock in the second quarter.

Our strong second-quarter performance gives us confidence about our performance for the remainder of the year. We expect to sustain strong revenue growth in the second half of 2014, as we capitalize on the growing late-stage and commercial product pipeline in small-molecule manufacturing, the ramp-up of our biologics manufacturing business, and investments in new businesses. We raise our full-year 2014 revenue guidance range from the previous $660-$670 million to $665-$670 million and increase our guidance for full-year 2014 GAAP and non-GAAP diluted EPS.

"We remain committed to building the premier open-access R&D platform that enables anyone and any company to discover and develop innovative medicines to benefit the world's patients," Dr. Li concluded.

Full-Year 2014 Financial Guidance

WuXi PharmaTech updates its full-year 2014 financial guidance:

• Total net revenues of $665-$670 million, compared to previous guidance of $660-$670 million
• GAAP diluted earnings per ADS of $1.55-$1.59, compared to previous guidance of $1.53-$1.58
• Non-GAAP diluted earnings per ADS of $1.82-$1.86, compared to previous guidance of $1.80-$1.85
• Capital expenditures of $95-$100 million, compared to previous guidance of about $85 million, driven primarily by capacity expansion in small-molecule manufacturing and investment in laboratories and technology in genomics, biologics, and biology

Third-Quarter 2014 Financial Guidance

WuXi PharmaTech provides the following third-quarter 2014 financial guidance:

• Total net revenues of $171-$173 million
• GAAP diluted earnings per ADS of $0.40-$0.42
• Non-GAAP diluted earnings per ADS of $0.48-$0.50

SHANGHAI, June 20, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice (GLP) inspection by the U.S. Food and Drug Administration (FDA) with no major observations. This was the first FDA GLP inspection in the facility's five years of operation. The inspection was extensive, lasting five days and including the review of numerous processes and the audit of four studies. WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.

"The outcome of the FDA inspection further demonstrates the consistency of our GLP compliance and quality services following the excellent results of earlier OECD and CFDA inspections," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

SHANGHAI, May 28, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services. The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.

"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

SHANGHAI, May 23, 2014 /PRNewswire/ -- Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced a strategic biomarker collaboration.

Through this collaboration, Targos will provide know-how, services, and the quality standards to support WuXi's bioanalytical work for pharmaceutical customers. The collaboration will focus on the validation and analysis of clinical tissue biomarkers in cancer. Targos will also provide its internationally known training and education to support pathologists and histotechnologists in generating accurate, objective, and reproducible diagnostic results. By adding these new molecular pathology testing services from Targos, WuXi will provide customers with a comprehensive platform of services in soluble, cell, and tissue biomarkers.

"We are pleased to have found in WuXi a partner who shares our vision of offering customers the highest-quality biomarker services," said Dr. Thomas Henkel, CEO of Targos.

"This agreement with Targos advances WuXi's mission of offering our customers the broadest range of capabilities to support their drug development," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

First-Quarter 2014 Financial Results

• Net Revenues Increased 11.3% Year Over Year to $146.7 Million
• Non-GAAP Diluted Earnings Per ADS Declined 14.3% Year Over Year to $0.30; Excluding Mark-to-Market Loss on Foreign-Exchange Forward Contracts, Non-GAAP Diluted Earnings Per ADS Increased 46.3% to $0.49

Management Comment

"WuXi started the year with a good first quarter," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Through strong revenue growth and good cost control, we exceeded our revenue and diluted EPS guidance for the quarter. We also made strong investment to sustain our growth."

"Our revenue growth was led by small-molecule manufacturing, biologics, and medicinal chemistry," Dr. Li continued. "We expect year-over-year revenue growth to accelerate in the coming quarters as new projects start to generate revenues across the board. The favorable biotech funding environment in the U.S. will generate new business throughout our organization in the next few years as our integrated drug discovery and development platform enables biotech companies to utilize our capabilities and capacity to rapidly advance their product pipelines.

"While achieving good revenue growth, we are investing in new capabilities, including talent, laboratories, and technologies, particularly in manufacturing, biologics, genomics, R&D, sales and marketing, and information technology, to drive future revenue growth. Our largest current investment is a two-year, $100 million expansion of our manufacturing facilities in Changzhou, which will double our current capacity and meet growing demand in both research manufacturing and commercial manufacturing.

"A mark-to-market loss on foreign-exchange forward contracts of $13.9 million in the quarter resulted from the depreciation of the RMB versus the U.S. dollar of about 3%, beginning in February. This loss was partially offset by operating margin improvement caused in part by the same currency movement, as well as by a $5.0 million gain from the sale by our corporate venture fund of an investment in an IPOed company. We have revised our full-year 2014 GAAP and non-GAAP earnings per ADS guidance to reflect these events. Apart from this mark-to-market loss, our financial performance in 2014 is meeting or exceeding our previous expectations.

"The company remains focused on its mission of building the best open-access platform of services and technologies to enable anyone and any company to discover, develop, and commercialize healthcare products to benefit the world's patients," Dr. Li concluded.

Full-Year 2014 Financial Guidance

WuXi PharmaTech announces the following full-year 2014 financial guidance:

• Total net revenues of $660-670 million, the same as previous guidance
• GAAP diluted earnings per ADS of $1.53-$1.58, including mark-to-market losses on foreign-exchange forward contracts of $0.20per ADS; GAAP diluted earnings per ADS of $1.73-$1.78, excluding mark-to-market gains or losses on foreign-exchange forward contracts
• Non-GAAP diluted earnings per ADS of $1.80-$1.85, including mark-to-market losses on foreign-exchange forward contracts of$0.20 per ADS; non-GAAP diluted earnings per ADS of $2.00-$2.05, excluding mark-to-market gains or losses on foreign-exchange forward contracts
• Capital expenditures of about $85 million, a year-over-year increase of about 50%, driven primarily by capacity expansion in small-molecule manufacturing and investment in laboratories and technology

Second-Quarter 2014 Financial Guidance

WuXi PharmaTech provides the following second-quarter 2014 financial guidance:

• Total net revenues of $160-162 million
• GAAP diluted earnings per ADS of $0.39-$0.41
• Non-GAAP diluted earnings per ADS of $0.46-$0.48

SHANGHAI, May 12, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, announced today that it has completed an expansion of its materials characterization testing facility in St. Paul, Minnesota.

A new 20,000-square-foot laboratory will offer expanded capacity for existing services, like particle identification and extractable/leachable testing, and add a new service————dynamic light scattering for nanoparticle characterization. These services are required by the FDA for filings of medical devices or biologics. The expansion is designed on a flexible floor plan that allows rapid scale-up of technologies to increase capacities for chemical analysis of medical materials. The new expanded laboratory will begin operation by the end of June.

"WuXi is committed to helping medical device and biologics companies bring their products to market faster," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This facility and WuXi's trained staff will better serve our customers' growing need to quantify the chemical safety of materials used in medical devices and biologics."

SHANGHAI, May 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development (R&D) services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd., has begun construction of a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai. The new construction aims to meet the rapidly growing demand for WuXi's manufacturing services, which have quadrupled their revenues in the past four years.

The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Facilities constructed in phase 1 will double the company's current manufacturing capacity and be operational by the fourth quarter of 2015. Upon completion of the entire project, the site will triple current capacity and can have more than 1,500 employees, including chemists, production staff, and supporting staff, to seamlessly move new chemical entities from early stage process development through preclinical and clinical deliveries to commercial production.

"This project marks an important milestone in STA's mission of building a fully integrated API development and manufacturing platform," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients."

SHANGHAI and TAIPEI, May 5, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX) and TaiMed Biologics today announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi's biologics facilities for ongoing treatment of patients under investigator-sponsored IND's. This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which marks an important milestone of WuXi's investment to expedite global development of innovative biologics.

Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. It is being developed by TaiMed Biologics for the treatment of HIV/AIDS infection.

The drug substance of ibalizumab was manufactured at WuXi's cell culture manufacturing facility, which recently received an honorable mention facility-of-the-year award by ISPE. The ibalizumab drug product batch approved by the FDA was manufactured at the newly completed state-of-the-art cGMP parenteral manufacturing facility located within the same campus as the cell culture facility at Wuxi city. The automated filling line can accommodate 2-50mL liquid and lyophilized vial products for global clinical trials and product launch.

"We congratulate TaiMed for progressing ibalizumab further in development and bringing this important drug one step closer to approval," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "WuXi is proud to serve as a gateway for developing novel biologics in China. Our integrated biologics discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

"TaiMed is pleased with the speed and excellent execution of this project to ensure the success of this important drug. We look forward to the next phase of collaboration with WuXi to successfully bring the drug to marketing approval," said Dr. James Chang, Chief Executive Officer of TaiMed Biologics.

SHANGHAI, April 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its analytical and stability testing facilities, located in Shanghai Waigaoqiao Free Trade Zone, have successfully passed an FDA general GMP inspection. This achievement brings regulatory advantages and potential expedited approval to clients who use these WuXi services for their NDA/ANDA filings and commercial analytical and stability testing. The clinical trial materials manufacturing for drug products (CTM), packaging and labeling facilities were also inspected and found to be in compliance.

"This favorable FDA inspection outcome, in addition to last year's MPA (EMA) approval, reflects the quality of our analytical and stability testing and CTM facilities, the robustness of our quality assurance system, and the high caliber of our employees," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We are committed to building operations with the highest standards of quality across our entire platform of R&D services."

SHANGHAI, April 29, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that it has broken ground on a new facility in Philadelphia for the manufacture of cell therapies. The facility is expected to become operational in the second quarter of 2015.

The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility. This expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.

Located in the Philadelphia Navy Yard, the new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.

"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr. Ge Li, Chairman and CEO of PharmaTech.

SHANGHAI and HONOLULU, April 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, and TruTag Technologies, Inc., developer of the leading edible, covert security platform to address the global product counterfeiting challenge, today announced that WuXi Corporate Venture Fund has made an investment in TruTag. In addition, WuXi and TruTag will explore collaborations to offer WuXi's global customers the TruTag on-dose authentication solution to help prevent counterfeiting and to enhance drug safety.

TruTag microtags ("TruTags^®") are inert and edible and can integrate into the fabric of a product without packaging or labels - much like fingerprints on a human being - for the authentication of food, drugs, electronics, consumer products, and industrial components. Millions of optical patterns can be embedded into a TruTag, a dust-sized particle smaller than the width of a human hair. Using this technology, brand owners, including pharmaceutical companies, will be able to field-read finished tablets circulating in the wholesale and retail market to determine the authenticity and provenance of medicines, including detailed information such as site and date of manufacture, lots, and other critical data.

"TruTag is very excited to work with WuXi to explore the development of our on-dose authentication solution for WuXi's pharmaceutical customers," said Dr. Hank C.K. Wuh, Chairman of TruTag Technologies. "This innovative technology is an important new weapon in fighting the growing global problem of counterfeit drugs."

"WuXi is pleased to invest in this cutting-edge technology and to explore its further development to enhance patient safety and protect our customers' intellectual property," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

SHANGHAI and SEATTLE, March 11, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider based in Seattle, today announced a biomarker collaboration.

In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi's own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.

"We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi's biomarker capabilities in support of our clients' clinical development," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Biomarkers are a new and important tool in the development of personalized medicines for many serious diseases."

"Partnering with WuXi enables us to realize considerable value in our biomarker assets," said Ronald Helm, CEO of Pacific Biomarkers. "This agreement will allow us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China."

SAN DIEGO and SHANGHAI, March 10, 2014 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations inChina and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

This new investment will enable WuXi's clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world's most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region.

The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi's genomics lab also provides assay development, validation, and testing services.

"This investment in cutting-edge gene sequencing technology significantly strengthens WuXi's broad, integrated platform of R&D services," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It advances our mission of enabling anyone and any company to use our R&D platform to discover and develop innovative medicines to benefit the world's patients."

The HiSeq X Ten is the world's first platform to deliver full coverage human genomes for $1,000, including typical instrument depreciation, DNA extraction, library preparation, and estimated labor. Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten can sequence approximately 18,000 samples annually with high-quality, high-coverage sequencing. It is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than three days or up to 600 gigabases (Gb) per day, per system.

"We are pleased that WuXi has chosen the HiSeq X Ten to serve its clients with state-of-the-art gene sequencing capabilities," said Jay Flatley, CEO of Illumina. "Illumina's leadership in the development of genomics technologies and WuXi's leadership in offering high-quality R&D services to leading biopharmaceutical companies are a perfect fit."

Fourth-Quarter 2013 Financial Results

• Fourth-quarter 2013 net revenues increased 25.1% year over year to $157.2 million.
• Non-GAAP diluted earnings per ADS grew 38.4% year over year to $0.53 due to the 42.0% increase in non-GAAP net income, partially offset by a higher number of outstanding ADSs as a result ofvesting and exercise of shares under the employee stock option and restricted stock programs.

"I am proud of WuXi's accomplishments in the fourth quarter and throughout 2013," said Dr. Ge Li, Chairman and Chief Executive Officer. "We are balancing present and future performance: both achieving strong current revenue and income growth and making the investments necessary to sustain growth for the long term. Through strong revenue growth and good cost control in the fourth quarter, we exceeded our revenue and diluted EPS guidance for the third consecutive quarter. All segments of the company contributed to our fourth-quarter revenue growth, with particularly good performances by small-molecule manufacturing, biologics, and integrated drug discovery services. Effective management of our foreign-exchange exposure again led to significant realized and mark-to-market gains on foreign-exchange forward contracts in the fourth quarter.

"With the 2014 financial guidance that we provide today, we express our belief that many of the favorable trends of 2013 will continue in 2014," Dr. Li continued. "We expect year-over-year revenue growth of 14-16% in 2014, driven by broad-based business growth in all our service segments. We expect 7-10% diluted EPS growth on a GAAP and non-GAAP basis in 2014, reflecting strong revenue growth and investment in talent, laboratories, and technologies, particularly in manufacturing, biologics, genomics, R&D, sales and marketing, and information technology.

"WuXi is transitioning from being an R&D service provider to becoming an R&D service and solution provider by creating an open-access technology and service platform that enables anyone and any company to discover, develop, and commercialize innovative healthcare products to benefit the world's patients," Dr. Li concluded. "With such a platform, the biopharmaceutical industry's great minds can realize their dreams of introducing important new therapeutics for patients faster and more cost-effectively."

Full-Year 2014 Financial Guidance

WuXi PharmaTech provides the following full-year 2014 financial guidance:

• Total net revenues of $660-670 million, or 14-16% year-over-year growth
• GAAP diluted earnings per ADS of $1.68-$1.73 and non-GAAP diluted earnings per ADS of $1.95-$2.00, representing 7-10% year-over-year growth
• Capital expenditures of about $85 million, a year-over-year increase of about 50%, driven primarily by capacity expansion in small-molecule manufacturing and investment in laboratories and technology

First-Quarter 2014 Financial Guidance

WuXi PharmaTech provides the following first-quarter 2014 financial guidance:

• Total net revenues of $143-145 million
• GAAP diluted earnings per ADS of $0.31-$0.33*
• Non-GAAP diluted earnings per ADS of $0.36-$0.38*

* In light of recent depreciation of the RMB versus the U.S. dollar and potential related volatility, for purposes of providing our first-quarter 2014 guidance we have not considered the potential mark-to-market gain or loss on foreign-exchange forward contracts.

SHANGHAI, Nov. 15, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll (STA) Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc. (Nasdaq: PCYC). This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with the expedited New Drug Application submission and final approval by the U.S. Food & Drug Administration (FDA).  After an expedited review by the FDA, IMBRUVICA received approval on November 13, 2013, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.  In the GMP pre-approval inspection of WuXi's manufacturing facilities in August, no Form 483 observations were issued by the FDA. 

IMBRUVICA is a first-in-class, oral therapy and is a new agent that inhibits a protein called Bruton's tyrosine kinase (BTK).  BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells.  IMBRUVICA blocks signals that tell malignant B cells to grow and divide uncontrollably.  IMBRUVICA has been granted three Breakthrough Therapy Designations by the FDA, a first for an oncology drug.  These designations are intended to expedite the development and review of drugs for serious or life-threatening conditions.  To date, nine Phase III clinical trials have been initiated with IMBRUVICA and 37 clinical trials are currently registered on www.clinicaltrials.gov.

"It is important that we work with a development partner with expertise in both clinical and commercial supply, as well as U.S. and worldwide GMP regulations, to ensure reliable quality supply to patients," commented Heow Tan, Chief of Technical Operations at Pharmacyclics.  "STA's extensive experience will help us meet the demands of clinical and commercial supply for IMBRUVICA."

"We are very pleased and honored that Pharmacyclics has selected STA, WuXi's small-molecule development and manufacturing business unit, as a key partner for this supply," said Dr. Ge Li, Chairman and CEO of WuXi.  "WuXi is determined to help our partners introduce innovative breakthrough drugs like IMBRUVICA to benefit patients around the world."

Third Quarter 2013 Financial Results

• Net revenues increased 16.6% year over year to $146.7 million.
• Diluted earnings per ADS (Non-GAAP) was $0.48 vs. last years $0.37

Management Comment

"WuXi achieved solid, broad-based revenue growth and stable margins in the third quarter," said Dr. Ge Li, Chairman and Chief Executive Officer. "As a result, we again exceeded our financial guidance for the quarter. We expect this strong growth to continue throughout the remainder of 2013 and are increasing our full-year 2013 EPS guidance.

"While achieving current growth, we are also making the investments necessary to sustain growth," Dr. Li continued. "In small-molecule manufacturing, we are planning to construct new research manufacturing and commercial manufacturing facilities that will substantially increase our capacity. In August 2013, we successfully completed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration of our commercial manufacturing facility in Jinshan for the production of an advanced intermediate for a product with an NDA under FDA review, without the issuance of a Form 483.

"Biologics is another area of current investment that will drive future revenue growth. We believe we have built the premier biologics drug discovery, development, and manufacturing business in China, and we expect it will be one of our fastest-growing businesses.

"Genomics is another area where WuXi is demonstrating leadership in China. We recently received CLIA certification from the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services for our genomics clinical laboratory in Shanghai, the only laboratory in China to receive such certification. Receipt of a CLIA certificate allows WuXi's genomics laboratory to undertake certain clinical trial gene sequencing projects.

"These and other achievements demonstrate that we are succeeding in our mission of building an open-access technology and capability platform that enables anyone and any company to discover and develop therapeutic products to benefit patients," Dr. Li concluded.

Full-Year 2013 Financial Guidance

WuXi PharmaTech updates its full-year 2013 financial guidance as follows:

• Total net revenues of $574-578 million, or 15-16% year-over-year growth, compared to previous guidance of $572-578 million
• GAAP and non-GAAP gross margin and operating margin comparable to those in 2012, the same as previous guidance
• GAAP diluted earnings per ADS of $1.51-$1.55, compared to previous guidance of $1.38-$1.44
• Non-GAAP diluted earnings per ADS of $1.73-$1.77, compared to previous guidance of $1.61-$1.67
• Capital expenditures of about $60 million, the same as previous guidance

Fourth-Quarter 2013 Financial Guidance

WuXi PharmaTech provides the following fourth-quarter 2013 financial guidance:

• Total net revenues of $153-157 million, or 22-25% year-over-year growth
• GAAP diluted earnings per ADS of $0.38-$0.42
• Non-GAAP diluted earnings per ADS of $0.44-$0.48

SHANGHAI, Nov. 4, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced a licensing agreement with Mayo Clinic's Center for Individualized Medicine to expand WuXi's collection of patient-derived xenograft (PDX) mouse models.  These models will support the cancer drug discovery and personalized medicine efforts of WuXi's global customers.

Under this agreement, WuXi has been granted an exclusive license for a panel of patient-derived xenograft models for prevailing cancers in Western countries that have been developed in connection with the center's research and patient care.  The Mayo collection supplements WuXi's unique and extensive Chinese PDX collection, which includes more than 500 Chinese patient-derived xenograft models, more than 220 of which have been deep-sequenced using whole exome sequencing at 100X.  By combining PDX models derived from cancer tissues of patients representing Chinese and Western ancestries, WuXi is creating a single platform to allow its global customers to select highly relevant models with a higher probability of success for testing targeted therapies.

"This agreement with the internationally renowned Mayo Clinic enables WuXi to provide the global research community with a unique single resource that will help advance cancer research through a more relevant and clinically directed approach," said Dr. Ge Li, Chairman and CEO of WuXi.  "We look forward to working with world-class organizations like Mayo Clinic to further strengthen our integrated, open-access R&D services platform, which enables anyone and any company to discover and develop new medicines for improved patient care."

"We are delighted to work with WuXi, an organization with a strong reputation and industry leadership, to make our PDX models broadly available to the global cancer research community," said Dr. Gianrico Farrugia, Director of Mayo Clinic's Center for Individualized Medicine. "We hope use of these models leads to more predictive approaches to the discovery and development of personalized cancer therapies for patients."

Mayo Clinic has a financial interest in the technology mentioned in this news release.  Revenue Mayo receives is used to support the clinic's not-for-profit mission in patient care, education and research.

SHANGHAI and TAIPEI, Oct. 30, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it had completed a cell culture capacity expansion, including two 2000L disposable bioreactors that are ready for cGMP manufacturing. Previously WuXi AppTec had built a state-of-the-art cGMP biologics manufacturing facility with two cell culture suites containing a 500L and a 1000L disposable bioreactor, respectively. As a result of this new expansion, WuXi AppTec operates the largest biologics facility with disposable bioreactors in China and the largest disposable bioreactor in the world. The facility has passed GMP audits from global clients and an audit by former U.S. FDA biologics inspectors. WuXi AppTec is now poised to support Phase III clinical manufacturing and initial commercial launch for therapeutic antibody and recombinant protein drugs. 

WuXi AppTec also announced completion of the first run of the 2000L disposable bioreactor using an NS0 mouse myeloma cell line for TaiMed Biologics' ibalizumab, a novel CD4 entry inhibitor for the treatment of HIV/AIDS infection. This event marks an important milestone in the global biologics manufacturing industry. Growing NS0 cells in disposable bioreactors entails significant technical challenges, and there are few reported cases of growing NS0 cells in large disposable bioreactors. Through intensive process research and development, WuXi AppTec reproduced in disposable bioreactors a manufacturing process originally implemented in traditional stainless steel bioreactors, with comparable process performance and product quality.

"Successful completion of our biologics facility expansion and the subsequent 2000L run mark important milestones in WuXi AppTec's mission of building first-class biologics manufacturing capabilities in China," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec.  "Although there is overcapacity in biologics manufacturing facilities globally, our biologics manufacturing facility is the only one in China that meets global cGMP standards. Through this expansion, we can quickly address increasing market demand for high-quality and cost-effective manufacturing of biologics. The first 2000L run also showcases our solid development and scale-up capabilities in mammalian cell culture. We continue to invest to build our integrated open-access biologics discovery, development, and manufacturing platform to serve our global clients and to play a pivotal role as the gateway for introducing biologics into the Chinese market."

"WuXi AppTec has made excellent progress in producing clinical-trial supplies for ibalizumab, an important new medicine for global patients," said Dr. James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable manufacturing partner as we enter into late-phase trials of ibalizumab in the United States and Asi

SHANGHAI, October 30, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China andthe United States, announced today that the small molecule API and advanced intermediate manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA) completed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration with no Form 483 issued.

STA has built a substantial manufacturing pipeline of small molecule APIs and advanced intermediates for our global clients through its integrated platform, which extends from process research and research manufacturing to commercial manufacturing. This inspection outcome confirms STA's capabilities in helping the clients move their new chemical entities through clinical development stages and eventually to commercial launch in the global market.

"The result of this inspection speaks to WuXi's high standards of quality," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We continue to leverage our knowledge and that of our partners to build and operate a first-class quality system in China that meets global regulatory requirements."

Second Quarter 2013 Financial Results

• Net Revenues Increased 9.2% Year Over Year to $142.3 Million
• GAAP Diluted Earnings Per ADS Grew 45.5% Year Over Year to $0.41
• Non-GAAP Diluted Earnings Per ADS Increased 41.9% from $0.33 Year Over Year to $0.46

Management Comment

"WuXi continues to make progress in building a broad, integrated platform of R&D services that will enable anyone and any company to discover and develop medicines more efficiently and cost effectively," said Dr. Ge Li, Chairman and Chief Executive Officer. "This integrated platform does more than simply provide convenience to clients; it helps them realize their dream of being a drug discoverer and developer.

"By serving our customers well, we are achieving solid, broad-based revenue growth," Dr. Li continued. "We exceeded our second-quarter 2013 revenue guidance, driven by excellent performances by China-based Laboratory Services and Manufacturing Services. We also exceeded our second-quarter 2013 EPS guidance. Year-over-year GAAP diluted EPS growth of 45.5% benefited from this revenue performance, gross margin improvement, large mark-to-market gains from foreign-exchange forward contracts, and lower tax expense.

"We are also building businesses to sustain growth in 2014 and beyond. Revenues from biologics services grew strongly in the second quarter and will be one of the key drivers of revenue and earnings growth for the next several years. Commercial manufacturing has a growing pipeline of products, several of which have received breakthrough designation by the U.S. FDA. And our joint venture WuXiPRA has named an experienced executive, Dr. James Pusey, as President and General Manager to lead it to the forefront of China's clinical research services business.

"WuXi is also effectively controlling its costs through continuous operational improvements, increased productivity, and implementation of a company-wide Lean Sigma program. We continue to expect to achieve gross margin and operating margin in 2013 comparable to 2012, as businesses like small-molecule drug development and biologics services ramp up their revenues, achieve scale, and provide solid returns on investment.

"Our strong second-quarter performance gives us confidence to increase full-year 2013 revenue guidance to $572-$578 million and full-year 2013 diluted EPS guidance to $1.38-$1.44 GAAP and $1.61-$1.67 non-GAAP," Dr. Li concluded. "We are investing in capabilities and capacity to sustain long-term revenue and earnings growth. Capital expenditures will increase in the second half of the year as planned and total about $60 million for the full year. Our free cash flow has been quite strong in recent quarters, and we will continue to seek opportunities to buy back shares."

Full-Year 2013 Financial Guidance

WuXi PharmaTech updates its full-year 2013 financial guidance as follows:

• Total net revenues of $572-578 million, or 14-16% year-over-year growth, compared to previous guidance of $565-575 million, or 13-15% growth
• GAAP and non-GAAP gross margin and operating margin comparable to those in 2012, the same as previous guidance
• GAAP diluted earnings per ADS of $1.38-$1.44, compared to previous guidance of $1.26-$1.30
• Non-GAAP diluted earnings per ADS of $1.61-$1.67, compared to previous guidance of $1.49-$1.53
• Capital expenditures of about $60 million, the same as previous guidance

Third-Quarter 2013 Financial Guidance

WuXi PharmaTech provides the following third-quarter 2013 financial guidance:

• Total net revenues of $143-145 million
• GAAP diluted earnings per ADS of $0.32-$0.34
• Non-GAAP diluted earnings per ADS of $0.38-$0.40

• Net Revenues Increased 11.7% Year Over Year to $131.9 Million
• GAAP Diluted Earnings Per ADS Grew 7.2% Year Over Year to $0.30
• Non-GAAP Diluted Earnings Per ADS Increased 7.5% Year Over Year to $0.35
• Company Reconfirms Full-Year 2013 Guidance

Management Comment

"I am pleased to announce that WuXi began 2013 with a solid first quarter," said Dr. Ge Li, Chairman and Chief Executive Officer. "We achieved 11.7% year-over-year revenue growth, 7.2% GAAP diluted EPS growth, and 7.5% non-GAAP diluted EPS growth in the quarter, exceeding our previous guidance in all three measures. This result gives us confidence to reconfirm our guidance for full-year 2013.

"WuXi is succeeding on several fronts at once," Dr. Li continued. "We are achieving double-digit, broad-based revenue growth, while effectively improving operating efficiency and controlling our costs to maintain stable margins. We are investing in capabilities and capacity to sustain strong revenue and earnings growth for years to come. In so doing, WuXi is making progress toward the goal of building an open-access technology platform and integrated services offerings that will enable anyone and any company to discover and develop medicines efficiently and cost-effectively. And we are returning capital to shareholders through share purchases."

Full-Year 2013 Financial Guidance

The company reconfirms the following full-year 2013 financial guidance:

• Total net revenues of $565-575 million, or 13-15% year-over-year growth
• GAAP diluted earnings per ADS of $1.26-$1.30
• Non-GAAP diluted earnings per ADS of $1.49-$1.53
• Capital expenditures of about $60 million

The company provides the following new full-year 2013 financial guidance:

• GAAP and non-GAAP gross margin and operating margin comparable to those in 2012

Second-Quarter 2013 Financial Guidance

The company provides the following second-quarter 2013 financial guidance:

• Total net revenues of $138-140 million
• GAAP diluted earnings per ADS of $0.34-$0.35
• Non-GAAP diluted earnings per ADS of $0.39-$0.40

First-Quarter 2013 Non-GAAP Results

• Non-GAAP financial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated deferred tax impact.
• Non-GAAP gross profit increased 11.6% year over year to $48.5 million, mainly due to the broad-based revenue growth discussed above. Non-GAAP gross margin was flat year-over-year at 36.8%, as the benefits of improved productivity were fully offset by the effects of increasing labor costs in China, appreciation of the RMB versus the U.S. dollar, investments in new businesses, and lower pricing in synthetic chemistry services.        
• Non-GAAP operating income increased 9.8% year over year to $26.7 million, primarily due to the 11.6% increase in non-GAAP gross profit, partially offset by higher operating expenses, particularly selling and marketing expenses and research and development expenses. Operating margin decreased slightly to 20.2% from 20.6% due to this increase in operating expenses.
• Non-GAAP net income grew 3.7% year over year to $25.4 million due to the 9.8% increase in non-GAAP operating income, offset by higher income tax expense primarily due to the increase in taxable income and the reversal of an uncertain tax provision in the first quarter of 2012.
• Non-GAAP diluted earnings per ADS grew 7.5% year over year to $0.35 due to the 3.7% increase in net income and a lower number of outstanding ADSs as a result of share buybacks in 2012.

"I am pleased to announce that WuXi began 2013 with a solid first quarter," said Dr. Ge Li, Chairman and Chief Executive Officer. "We achieved 11.7% year-over-year revenue growth, 7.2% GAAP diluted EPS growth, and 7.5% non-GAAP diluted EPS growth in the quarter, exceeding our previous guidance in all three measures. This result gives us confidence to reconfirm our guidance for full-year 2013.

"WuXi is succeeding on several fronts at once," Dr. Li continued. "We are achieving double-digit, broad-based revenue growth, while effectively improving operating efficiency and controlling our costs to maintain stable margins. We are investing in capabilities and capacity to sustain strong revenue and earnings growth for years to come. In so doing, WuXi is making progress toward the goal of building an open-access technology platform and integrated services offerings that will enable anyone and any company to discover and develop medicines efficiently and cost-effectively. And we are returning capital to shareholders through share purchases."

Full-Year 2013 Financial Guidance

The company reconfirms the following full-year 2013 financial guidance:

• Total net revenues of $565-575 million, or 13-15% year-over-year growth
• GAAP diluted earnings per ADS of $1.26-$1.30
• Non-GAAP diluted earnings per ADS of $1.49-$1.53
• Capital expenditures of about $60 million

The company provides the following new full-year 2013 financial guidance:

• GAAP and non-GAAP gross margin and operating margin comparable to those in 2012

Second-Quarter 2013 Financial Guidance

The company provides the following second-quarter 2013 financial guidance:

• Total net revenues of $138-140 million
• GAAP diluted earnings per ADS of $0.34-$0.35
• Non-GAAP diluted earnings per ADS of $0.39-$0.40

GAITHERSBURG, Md., and SHANGHAI, September 11, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, a leading research and development outsourcing company, today announced that they have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.

MedImmune will provide technical and development expertise, while WuXi AppTec will provide local regulatory, manufacturing, pre-clinical and clinical trial support. When undertaking clinical trial development in China, the government requires local manufacture of medicines that have not been approved in other markets.

"We are pleased to partner with WuXi AppTec, a company with strong leadership in the Chinese pharmaceutical R&D sector, to help us address the healthcare needs of Chinese patients through the co-development of MEDI5117," said Bahija Jallal, Executive Vice President, Research & Development, MedImmune. "This strategic partnership will enable us to establish a leadership presence in developing novel biologics in China, complementing AstraZeneca's investment in this important emerging market."

The joint venture will control the development of MEDI5117 for autoimmune and inflammatory diseases in China, and the two companies will have equal ownership in the joint venture. AstraZeneca / MedImmune will have the option to acquire the full rights to commercialize MEDI5117; otherwise, the joint venture will have the right to commercialize the product. WuXi AppTec will earn revenue based on services provided to the joint venture. MedImmune will receive various milestone payments as the program progresses.

"WuXi is delighted to work with MedImmune, an innovative biologics company, to develop and manufacture a novel product for first use in China," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "WuXi is working to build long-term drug development partnerships with leading biopharmaceutical companies like MedImmune to help accelerate the development of novel medicines for the large and rapidly growing Chinese pharmaceutical market."

Today's announcement supports AstraZeneca's ongoing commitment to collaborating across Asia in ways that maximize the scientific and local knowledge of its partners and tap into the region's strong history of innovation.

The Chinese government's focus on healthcare reform, along with its investment in improving healthcare infrastructure and expanding medical insurance coverage, are expected to continue to drive growth and demand for quality medicines over the long term. China also continues to increase its biomedical R&D investment, fuelled by sustained GDP growth. The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010 and, according to IMS Health, is projected to grow to over $100 billion by 2014.

SHANGHAI and TAIPEI, August 28, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. This work will be completed at WuXi's biologics manufacturing facilities inChina and its biologics testing facilities in the United States.

"We are pleased that TaiMed Biologics has selected WuXi to manufacture ibalizumab for its global clinical trials because of WuXi's strong technical capabilities and high quality standards," said Edward Hu, Chief Operating Officer of WuXi PharmaTech. "WuXi's integrated biological drug discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

"TaiMed looks forward to working with WuXi to produce clinical-trial supplies of this important new medicine for patients," said James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable partner in WuXi for late-stage manufacturing as we further develop the subcutaneous formulation of our lead product, ibalizumab."

Highlights

• Net Revenues Increased 28.9% Year Over Year to $130.4 Million
• Laboratory Services Net Revenues Grew 24.7% Year Over Year to $93.6 Million
• China-Based Laboratory Services Net Revenues Increased 27.2% Year Over Year to $70.3 Million
• U.S.-Based Laboratory Services Net Revenues Increased 17.7% Year Over Year to $23.3 Million
• Manufacturing Services Net Revenues Grew 41.2% Year Over Year to $36.8 Million
• Net Revenues from China Operations Exceeded $100 Million for the First Time on a Quarterly Basis
• Share Repurchases Totaled $10.2 Million
• GAAP Diluted Earnings Per ADS Grew 13.4% Year Over Year to $0.28
• Non-GAAP Diluted Earnings Per ADS Increased 12.3% Year Over Year to $0.33
• Company Increases Full-Year 2012 Revenue Guidance to $488-$498 Million

Management Comment

"WuXi continues to build a comprehensive and integrated technology platform and service offerings that will enable anyone and any company to discover and develop new products efficiently and cost-effectively," Dr. Li concluded. "By building high-quality operations to better serve our customers, WuXi has become the leader in the Chinese pharmaceutical R&D services industry. We are well-positioned to take advantage of the trend of increasing pharmaceutical research and development outsourcing."

SHANGHAI, June 4, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, today commented on the conviction of a former employee for the theft of chemical compounds.

In 2011, a junior employee of WuXi PharmaTech, acting by himself, stole and sold for personal gain sample amounts of two patented chemical compounds made for a customer. Working together with the customer, WuXi PharmaTech cooperated with law enforcement authorities to identify the employee, who was apprehended and subsequently convicted under applicable Chinese law on May 22, 2012. The compounds in question were recovered.

WuXi PharmaTech has stringent intellectual property (IP) protection procedures and a zero-tolerance policy for any activity that damages the interests of its customers. This is the only known misappropriation of customer compounds in the company's 11 years of operations.

"We regret that one of our employees committed a crime on our premises," commented Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "The strong and trusting customer relationships we have built over the past 11 years are based in part on our culture of commitment to IP security. As in any company, there will always be the risk of damage caused by a determined criminal. At WuXi PharmaTech, customer IP protection is our lifeline and we are committed to working closely with our customers to ensure the security of their projects."

Dr. Li noted that this was an isolated case involving sample amounts of two patented compounds whose chemical structures are available in their respective patent filings. The company treats any breach of security protocols with the utmost seriousness and is undertaking an ongoing review to strengthen security measures to ensure the protection of customer IP. In addition, the company is intensifying employee training and strengthening oversight of facilities through increasing the number of both regular and unannounced laboratory and office inspections.

First quarter of 2012 Highlights.

• Net Revenues Increased 26.2% Year Over Year to $118.0 Million
• Manufacturing Services Net Revenues Grew 35.0% Year Over Year to $31.4 Million
• Laboratory Services Net Revenues Grew 23.2% Year Over Year to $86.6 Million
• China-Based Laboratory Services Net Revenues Increased 25.8% Year Over Year to $64.5 Million
• U.S.-Based Laboratory Services Net Revenues Increased 16.4% Year Over Year to $22.2 Million
• GAAP Diluted Earnings Per ADS Grew 15.8% Year Over Year to $0.28
• Non-GAAP Diluted Earnings Per ADS Increased 15.1% Year Over Year to $0.33
• Company Reconfirms 2012 Financial Guidance

Management Comment

"WuXi began 2012 with a strong first quarter, achieving 26.2% revenue growth," said Dr. Ge Li, Chairman and Chief Executive Officer. "This strong revenue growth was broad-based across all of our businesses. We met or exceeded all of our financial targets for revenues and margins for the quarter. And we continue to invest to build capabilities and to expand capacities in both laboratory services and manufacturing services. For example, our new Wuhan chemistry site began operations in February.

"WuXi is building a comprehensive and integrated technology platform and service offerings that will enable anyone and any company to discover and develop new products efficiently and cost-effectively," Dr. Li concluded. "China is becoming an important hub for pharmaceutical R&D in part because of China's pharmaceutical market, already the third largest in the world and growing very rapidly. By building high-quality operations to better serve our customers, WuXi has become the leader in the Chinese pharmaceutical R&D services industry. We are well-positioned to take full advantage of the significant long-term trend for increasing outsourcing of pharmaceutical research and development."

Beginning with this financial report for the first quarter of 2012, WuXi PharmaTech presents its results of operations for Process Chemistry under the Manufacturing Services segment rather than the Laboratory Services segment. Process Chemistry develops processes for making active pharmaceutical ingredients (APIs) and advanced intermediates and thus is more closely related to operations of the Manufacturing Services segment. Prior-year results in this report also reflect this reclassification.

Also beginning with the first quarter of 2012, WuXi PharmaTech presents other comprehensive income and its components in its Statement of Comprehensive Income in accordance with Accounting Standards Update 2011-05. For the periods presented herein, other comprehensive income consists of foreign currency translation adjustments resulting from the translation of our financial statements into our reporting currency, the U.S. dollar. The functional currency of ourChina-based operations is the RMB.

2012 Financial Guidance

The company maintains its full-year 2012 financial guidance:

• Total net revenues of $468-$488 million, or 15-20% year-over-year growth
• Growth in total net revenues of China-based Laboratory Services of 18-24% on a pro-forma basis reflecting the classification of Process Chemistry in Manufacturing Services for both years
• Growth in total net revenues of U.S.-based Laboratory Services of 6-9%
• Growth in total net revenues of Manufacturing Services of 13-18% on a pro-forma basis reflecting the classification of Process Chemistry in Manufacturing Services for both years
• Operating income margin of 17.5-19.0% on a GAAP basis, 20.0-21.5% on a non-GAAP basis
• Capital expenditures of about $70 million
• GAAP effective tax rate of about 17.5%

Second-Quarter 2012 Financial Guidance

The company provides the following second-quarter 2012 financial guidance:

• Total revenues of $124-$129 million, up 23-28% year over year
• Laboratory Services revenues (not including Process Chemistry) of $90-$92 million
• Manufacturing Services revenues (including Process Chemistry) of $34-$37 million
• Operating margin of 17.5-18.0% GAAP, 20.5-21.0% non-GAAP

Fourth-Quarter 2011 Highlights

• Net Revenues Increased 22.5% Year Over Year to $108.5 Million
• Manufacturing Services Net Revenues Grew 56.1% Year Over Year to $15.7 Million
• Laboratory Services Net Revenues Grew 18.2% Year Over Year to $92.8 Million
• China-Based Laboratory Services Net Revenues Increased 20.8% Year Over Year to $72.0 Million
• U.S.-Based Laboratory Services Net Revenues Increased 10.1% Year Over Year to $20.8 Million
• GAAP Diluted Earnings Per ADS Grew 35.1% Year Over Year to $0.31
• Non-GAAP Diluted Earnings Per ADS Increased 29.3% Year Over Year to $0.36

"WuXi completed a successful 2011 with a solid fourth quarter, driven by strong revenue performances in both Manufacturing Services and Laboratory Services," said Dr. Ge Li, Chairman and Chief Executive Officer. "Our year-over-year revenue growth was broad-based and was particularly strong in integrated medicinal chemistry, DMPK/ADME, formulation, toxicology, bioanalytical services, and commercial manufacturing. We exceeded our revenue guidance and met all of the rest of our guidance for the full year.

"We believe that 2012 will be a year of strong growth for all of our businesses. Our financial guidance for 2012 reflects 15-20% net revenue growth, anchored by projected China-based Laboratory Services revenue growth of 18-24% on a pro forma basis, resulting from increasing customer demand for our broad and integrated services. In 2012, we intend to make significant investments in new businesses, including biologics drug discovery, development and manufacturing services; clinical development services; biologics reagents; and genomics. We will also invest in expanding our existing business, including ramping up our Wuhan chemistry site; expanding our formulation and stability testing labs; and strengthening our leading position in integrated medicinal chemistry capabilities.

"WuXi is building an alternative R&D engine for the life-sciences industry," Dr. Li concluded. "This engine represents an integrated technology platform and service offerings that will enable anyone and any company to discover and develop medicines. China is rapidly becoming an important hub for pharmaceutical R&D, in part because of the rapid growth of China's large pharmaceutical market. WuXi is positioned well to continue to be a leader in the Chinese life-sciences industry by building capabilities and capacities to better serve our customers."

Beginning with financial reporting in the first quarter of 2012, WuXi PharmaTech will record its results of operations for Process Chemistry under Manufacturing Services rather than Laboratory Services. Process Chemistry develops processes for making active pharmaceutical ingredients (APIs) and advanced intermediates and thus is more closely related to operations of Manufacturing Services. Process Chemistry is managed as part of the Manufacturing Services business unit as of 2012. Full-year 2011 revenues for Process Chemistry were approximately $20.4 million.

• Third-Quarter 2011 Net Revenues Increased 24.0% Year Over Year to $104.0 Million 
• Manufacturing Services Net Revenues Grew 183.8% Year Over Year to $20.1 Million 
• Laboratory Services Net Revenues Grew 9.2% Year Over Year to $83.9 Million 
• China-Based Laboratory Services Net Revenues Increased 10.7% Year Over Year to $63.2 Million 
• GAAP Operating Income Increased 15.8% Year Over Year to $22.2 Million 
• Non-GAAP Operating Income Increased 10.1% Year Over Year to $24.9 Million 
• GAAP Diluted Earnings Per ADS Declined 53.8% Year Over Year to 27 Cents Due to Inclusion in the Prior-Year Results of a Termination Fee Relating to the Proposed Transaction with Charles River Laboratories and an Increase in the Effective Tax Rate
• Non-GAAP Diluted Earnings Per ADS Increased 2.6% Year Over Year to 31 Cents Due to an Increase in the Effective Tax Rate
• WuXi Refines Its Full-Year 2011 Guidance
• Board Member Jeff Leng Elected to Audit Committee

2011 Financial Guidance

The company updates its full-year 2011 financial guidance:

• Total net revenues of $402-406 million, including about $1.5 million from two months of combined revenue from the newly acquired Abgent and MedKey businesses
• Growth in net revenues of China-based Laboratory Services of 14-15%
• Growth in net revenues of U.S.-based Laboratory Services of about 6%
• Growth in net revenues of Manufacturing Services of at least 84%
• GAAP gross margin approximately equal to that in full-year 2010, and a year-over-year decline in non-GAAP gross margin of about 1.5 percentage points
• GAAP operating margin of about 21% and non-GAAP operating margin of about 24%
• Capital expenditures of $60-65 million 
• GAAP effective tax rate of about 18%

Second Quarter 2011 Results

Reported 2010 fourth quarter EPS of $0.28 vs. $0.21 estimate. 2011 revenue guidance is in line with analyst estimates of $400 million. Even though 2011 EPS is expected to be flat at $1.09,  seven out of the next eight quarters are forecast to grow nicely. We will track this stock closely. We need to inquire about the other income line, which contributed EPS of $0.39 to 2010 results.  WX is an ex- GeoBargain.  We will pull SAIC filings.

See outlook

See earnings review of all ChinaHybrids on our Blog.

Third-Quarter 2010 Highlights

• Net revenues grew 20% year over year to $83.8 million.

• GAAP operating income grew 31% and non-GAAP operating income grew 26% year over year.

• GAAP diluted earnings per ADS grew 205% year over year to 59 cents, driven by a strong operating performance and a termination fee relating to the proposed transaction with Charles River Laboratories.

• Non-GAAP diluted earnings per ADS grew 26% year over year to30 cents.

"WuXi continued a strong 2010 with an excellent third quarter," said Dr. Ge Li, Chairman and Chief Executive Officer. "Total company revenues grew 20% year over year, and each of our businesses delivered strong revenue growth in the quarter. GAAP net income grew by 209% year over year, driven by this strong revenue growth and receipt of a $30 million termination fee relating to the proposed merger transaction with Charles River. Non-GAAP net income grew year over year by 27%. This strong performance leads us once again to increase our net revenue and operating income guidance for 2010.

2010 Financial Guidance Update

We update our full-year 2010 financial guidance as follows:

• Total net revenues of $330-$333 million, or year-over-year growth of 22-23%, compared to previous guidance of $320-$325 million, or 19-20% growth.

• Growth in non-GAAP operating income of 28-32%, compared to previous guidance of 15-20%.

• Decline in GAAP gross margin of approximately two percentage points, compared to previous guidance of two to three percentage points.

• decline in non-GAAP gross margin of less than two percentage points, compared to previous guidance of two to three percentage points.

• Capital expenditures$48-$50 million, compared to previous guidance of $50 million.

• Effective tax rate of 13-15%, excluding merger-related costs and the termination fee related to the proposed Charles River transaction, as indicated in previous guidance.

Wuxi Pharmatech removed from the GeoBargain on the Radar List. PEG ratio is near 1 .

Added to the GeoBargain List on May 15, 2009 @ $6.35

Current Price: $16.15

Reached a high of $18.00 on November 30, 2009

Commenting on 2010 guidance, Edward Hu, chief operating officer and acting chief financial officer, said, "In 2010, we expect continued solid financial performance while we invest for the future. We expect that growth in total net revenues will significantly accelerate from 7% in 2009 to 15-19% in 2010, driven by broad-based demand for our integrated services platform. China Laboratory Services is expected to achieve revenue growth of 13-16%. Manufacturing Services revenues are expected to grow more than 70% year over year in 2010, benefiting from a large delivery in the first quarter and from generally improving demand. Revenues in U.S.-based Laboratory Services are expected to grow at a mid-single-digit rate. These projections assume very small revenue contributions from the large-scale manufacturing and toxicology businesses in 2010.

"Operating income in 2010 is expected to achieve growth of up to 10 percent compared to 2009, driven by strong revenue growth and increased leverage of SG&A. An expected 2-5 percentage point gross margin decrease, primarily in the second half of 2010, is due to several factors, including an increase in labor and depreciation expenses, expenses from the ramp-up of the toxicology and large-scale GMP manufacturing operations, and pricing pressure. We are working to improve our projected 2010 gross margins. We expect the growth rate in operating income to accelerate in 2011, driven by continued strong revenue growth from China-based laboratory services, meaningful revenues from toxicology and large-scale manufacturing, and improving margins."

Source: PR Newswire (March 8, 2010)